CURRICULUM VITAE

Name: **Won Seog Kim**

Kim, Won-Seog

Education:

1990 - M.D., College of Medicine, Seoul National University

1999 - Ph.D., College of Medicine, Seoul National University

2002-2004. postdoc visiting fellow, NHLBI, NIH, USA

Subspecialty Certification; Hematology-Oncology

Brief Chronology of Employment:

Mar. 1990 - Feb. 1991 Intern, Seoul National University Hospital

Mar. 1991 - Feb. 1995 Resident , Dept. of Internal Medicine, Seoul National University Hospital

Mar. 1995 - Feb. 1996 Fellow, Section of Medical Oncology, Dept. of Internal Medicine, Seoul National University Hospital

Mar. 1996 - Feb. 1997 Fellow, Section of Medical Oncology, Dept. of Internal Medicine, Samsung Medical Center. Seoul, Korea

Mar. 1997 - Feb. 1998 Staff, Division of Hematology-Oncology, Dept. of Medicine, Samsung Medical Center, Seoul, Korea

Mar. 1998 - Mar. 2000 Full-time lecturer, Division of Hematology-Oncology, Dept. of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea

Apr.2000 – Sep. 2004 Assistant Professor. Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center, Sungkyunkwan University , School of Medicine Seoul, Korea

Oct. 2004- Sep. 2010 Associate Professor. Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center, Sungkyunkwan University , School of Medicine Seoul, Korea

Sep.2010 – present Professor. Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center, Sungkyunkwan University , School of Medicine Seoul, Korea

Apr 2021-present Director , Division of hematology-Oncology Dept.of Medicine, Samsung Medical Center, Sungkyunkwan University , School of Medicine Seoul, Korea

Apr 2021 – present Director, CAR-T cell therapy center. Samsung medical center, Seoul, Korea

Societies:

Korean Medical Association

Korean Association of Internal Medicine

Korean Society of Hematology

ESMO

JSMO

Position and Honors

Leader of lymphoma service in Samsung medical center

Chairman of lymphoma working party of Korean society of hematology

Chairman of Consortium of improving survival of lymphoma (CISL)

Founding member of Asian lymphoma study group (ALSG)

Co-Chair of T cell lymphoma forum (TCLF)

Director of Samsung medical center CART-cell therapy center

Director of Division of Hematology-Oncology, Samsung Medical Center,

Scientific committee member of ESMO

Award

Outstanding Research Award from Korean Society of Hematology (2010)

Best Achievement in inpatient care(2006) and in Research(2007) from Samsung Medical Center ,

Outstanding senior researcher award from Korean society of hematology (2016).

Most cited publication 2020 from Korean Cancer association

Best Poster presentation 2023 from ESMO

BIBLIOGRAPHY

Comparative Effectiveness of Anbalcabtagene Autoleucel versus Tisagenlecleucel in Patients with Relapsed/Refractory Diffuse Large B-cell **Lymphoma**. Seo HJ, Yoo WH, Jung K, Kim JW, Shin JY, Kim JH, **Kim WS.** Cancer Res Treat. 2025 Jul 11. doi: 10.4143

Detection of HIV RNA after CAR-T Cell Therapy in A Relapsed/refractory Diffuse Large B-cell Lymphoma Patient: Possibility of False Positivity and Clinical Implications. Yoon SE, Huh K, Kim TY, Huh HJ, Kim SJ, Kim WS. Cancer Res Treat. 2025 Jun 30. doi: 10.4143

Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell **lymphoma**. Bartlett NL, Hahn U, **Kim WS**, Fleury I, Laribi K, Bergua JM, Bouabdallah K, Forward N, Bijou F, MacDonald D, Portell CA, Ghesquieres H, Nowakowski G, Yasenchak CA, Patterson M, Ho L, Rustia E, Fanale M, Jie F, Kim JA. Future Oncol. 2025 Jul;21(16):1965-1983.

Real-world data analysis of survival outcomes of patients with primary mediastinal large B-cell **lymphoma** treated with immunochemotherapy: the role of consolidative radiation therapy. Lee YP, Cho J, Ko YH, Oh D, Kim SJ, **Kim WS**, Yoon SE.Blood Res. 2025 Apr 22;60(1):27.

Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell **lymphoma** therapy in Asia. Tan YH, Yoon DH, Davies AJ, Buske C, Boo YL, Somasundaram N, Lim F, Ong SY, Jeyasekharan A, Izutsu K, **Kim WS**, Chan JY.Discov Oncol. 2025 Feb 14;16(1):181. doi: 10.1007

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell **Lymphoma**. Bartlett NL, Hahn U, **Kim WS**, Fleury I, Laribi K, Bergua JM, Bouabdallah K, Forward N, Bijou F, MacDonald D, Portell CA, Ghesquieres H, Nowakowski G, Yasenchak CA, Patterson M, Ho L, Rustia E, Fanale M, Jie F, Kim JA. J Clin Oncol. 2025 Mar 20;43(9):1061-1072.

Mutational characteristics of extranodal NK/T-cell **lymphoma** analyzed in relation to clinical prognostic indices. Lee J, Yoon SE, Kim SJ, **Kim WS**, Cho J.Ann Hematol. 2024 Dec;103(12):5749-5757

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell **lymphoma** (STARGLO): a global phase 3, randomised, open-label trial. Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, **Kim WS**, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP. Lancet. 2024 Nov 16;404(10466):1940-1954

A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell **Lymphomas**. **Kim WS**, Shortt J, Zinzani PL, Mikhailova N, Radeski D, Ribrag V, Domingo Domenech E, Sawas A, Alexis K, Emig M, Elbadri R, Hajela P, Ravenstijn P, Pinto S, Garcia L, Overesch A, Pietzko K, Horwitz S. Clin Cancer Res. 2025 Jan 6;31(1):65-73.

Peripheral T- and natural killer-cell **lymphomas**: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up. d'Amore F, Federico M, de Leval L, Ellin F, Hermine O, **Kim WS**, Lemonnier F, Vermaat JSP, Wulf G, Buske C, Dreyling M, Jerkeman M; ESMO Guidelines Committees. Electronic address: clinicalguidelines@esmo.org; EHA Guidelines Committees. Electronic address: guidelines@ehaweb.org.Ann Oncol. 2025 Mar 14:S0923-7534(25)00059-6. doi: 10.1016/j.annonc.2025.01.023

Peripheral T- and natural killer-cell **lymphomas**: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up. d'Amore F, Federico M, de Leval L, Ellin F, Hermine O, **Kim WS**, Lemonnier F, Vermaat JSP, Wulf G, Buske C, Dreyling M, Jerkeman M; ESMO and EHA Guidelines Committees.Hemasphere. 2025 May 7;9(5):e70128. doi: 10.1002/hem3.70128. eCollection 2025 May

Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell **lymphomas**: A global PETAL Consortium study. Real-world data analysis of survival outcomes of patients with primary mediastinal large B-cell **lymphoma** treated with immunochemotherapy: the role of consolidative radiation therapy. Sorial MN, Han JX, Koh MJ, Boussi L, Li S, Duan R, Lu J, Lei MM, MacVicar CT, Freydman J, Malespini J, Aniagboso KN, McCabe SM, Peng L, Singh S, Iwasaki M, Eche-Ugwu IJ, Gabler J, Fernandez Turizo MJ, Garg A, Disciullo A, Chopra K, Ford J, Lenart A, Nwodo E, Barnes J, Koh MJ, Miranda E, Chiattone C, Stuver R, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim JS, Cho JY, Eipe T, Shet T, Epari S, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince HM, Hamouche R, Murdashvili T, Foss F, Gentilini M, Casadei B, Zinzani PL, Okatani T, Yoshida N, Yoon SE, **Kim WS**, Panchoo G, Mohamed Z, Verburgh E, Alturas JC, Al-Mansour M, Cabrera ME, Ku A, Bhagat G, Ma H, Sawas A, Kariya KM, Bhanushali F, Meharwal A, Mistry D, Kosovsky M, Yeterian M, O'Connor OA, Marchi E, Shen C, Shah D, Jain S. Br J Haematol. 2025 May 1. doi: 10.1111/bjh.20063.

.Determination of the appropriate chemotherapy for patients aged 80 years or older with diffuse large B cell **lymphoma**. Kim MJ, Cho J, **Kim WS**, Kim SJ, Yoon SE.Leuk Lymphoma. 2025 Mar 3:1-12

MiR-340-5p regulates PD-L1 and predicts pembrolizumab response in extranodal NK/T-cell **lymphoma**. Ryu KJ, Ji H, Park B, Yoon SE, Cho J, **Kim WS**, Kim HH, Kim SJ.Sci Rep. 2025 Feb 25;15(1):6

Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell **lymphoma** therapy in Asia. Tan YH, Yoon DH, Davies AJ, Buske C, Boo YL, Somasundaram N, Lim F, Ong SY, Jeyasekharan A, Izutsu K, **Kim WS**, Chan JY.Discov Oncol. 2025 Feb 14;16(1):181. doi: 10.1007/s12672-025-01860-5

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell **Lymphoma**. Bartlett NL, Hahn U, **Kim WS**, Fleury I, Laribi K, Bergua JM, Bouabdallah K, Forward N, Bijou F, MacDonald D, Portell CA, Ghesquieres H, Nowakowski G, Yasenchak CA, Patterson M, Ho L, Rustia E, Fanale M, Jie F, Kim JA.J Clin Oncol. 2025 Mar 20;43(9):1061-1072. doi: 10.1200/JCO-24-02242

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, **Kim WS**, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR.Haematologica. 2025 Jan 1;110(1):92-102

Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell **Lymphoma**. Kim SJ, Kim JJ, Park MR, Park B, Ryu KJ, Yoon SE, **Kim WS**, Shin S, Lee ST. Ann Lab Med. 2025 Jan 1;45(1):90-95.

Exosomal miR-155-5p drives ibrutinib resistance in B-cell **lymphoma**.Park B, Choi ME, Ryu KJ, Park C, Choi M, Yoon SE, **Kim WS**, Kim HH, Hong JY, Kim SJ. Exp Cell Res. 2024 Oct 1;442(2):114248. doi: 10.1016

Clinical Impact of Microbiome Characteristics in Treatment-Naive Extranodal NK/T-Cell **Lymphoma** Patients. Yoon SE, Kang W, Cho J, Chalita M, Lee JH, Hyun DW, Kim H, Kim SJ, **Kim WS.** Cancer Res Treat. 2025 Apr;57(2):597-611

Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell **lymphoma**: final analysis of phase IIb results. Rai S, **Kim WS**, Ando K, Choi I, Izutsu K, Tsukamoto N, Maruyama D, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Kato H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Haematologica. 2024 Oct 1;109(10):3357-3362

Long-term survival outcomes of 'watch and wait' in patients with bronchus-associated lymphoid tissue **lymphoma**: a multicenter real-world data analysis in Korea. Kwak K, Yoo KH, Choi YS, Park Y, Kim BS, Yoon SE, **Kim WS**, Kang KW, Kim SJ.Ann Hematol. 2024 Oct;103(10):4193-420

Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system **lymphoma**. Yi JH, Kim SJ, Yang DH, Do YR, Won JH, Baek D, Shin HJ, Kim DS, Kim HJ, Kang KW, Bae SH, Kwon JH, Kwon JH, Park BB, **Kim WS.** Br J Haematol. 2024 Nov;205(5):1773-1781.

CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell **lymphoma**. Zinzani PL, Wang H, Feng J, Kim TM, Tao R, Zhang H, Fogliatto L, Maluquer Artigal C, Özcan M, Yanez E, **Kim WS**, Kirtbaya D, Kriachok I, Maciel F, Xue H, Bouabdallah K, Phelps C, Chaturvedi S, Weispfenning A, Morcos PN, Odongo F, Buvaylo V, Childs BH, Dreyling M, Matasar M, Ghione P. Blood Adv. 2024 Sep 24;8(18):4866-4876

Peripheral T-cell **lymphoma**: From biology to practice to the future. O'Connor OA, Ma H, Chan JYS, Kim SJ, Yoon SE, **Kim WS.**Cancer Treat Rev. 2024 Sep;129:102793. doi: 10.1016/

Lymphoma Classifications, How to Develop a Future Unified Taxonomy. Campo E, Dierickx D, Dirnhofer S, Dunleavy K, Gaulard P, Hasserjian RP, Jaffe ES, **Kim WS**, King RL, Lim MS, Ott G, Piris MA, Salles G, Siebert R.J Clin Oncol. 2024 Sep 20;42(27):3177-3182

Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell **Lymphoma**: A Phase II CISL1701/BIC Study. Choi YS, Shim J, Kang KW, Yoon SE, Hong JS, Lim SN, Yhim HY, Kwon JH, Lee GW, Yang DH, Oh SY, Shin HJ, Eom HS, Yoon DH, Lee HG, Jeong SH, **Kim WS**, Kim SJ. Cancer Res Treat. 2025 Jan;57(1):267-279.

Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell **lymphoma**. Witzig T, Sokol L, **Kim WS**, de la Cruz Vicente F, Martín García-Sancho A, Advani R, Roncero Vidal JM, de Oña Navarrete R, Marín-Niebla A, Rodriguez Izquierdo A, Terol MJ, Domingo-Domenech E, Saunders A, Bendris N, Mackey J, Leoni M, Foss F.Blood Adv. 2024 Sep 10;8(17):4581-4592

Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell **lymphoma**. Yoon SE, Cho H, Berning P, Cho J, Kim HY, Yoon DH, Schmit N, Kim SJ, **Kim WS.**Ann Hematol. 2024 Oct;103(10):4171-4181

CAR T cells vs bispecific antibody as third- or later-line large B-cell **lymphoma** therapy: a meta-analysis. Kim J, Cho J, Lee MH, Yoon SE, **Kim WS**, Kim SJ.Blood. 2024 Aug 8;144(6):629-638

ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study. Maris M, Salles G, **Kim WS**, Kim TM, Lyons RM, Arellano M, Karmali R, Schiller G, Cull E, Abboud CN, Batlevi C, Kagiampakis I, Rebelatto MC, Lee Y, Kirby LC, Wang F, Bothos J, Townsley DM, Fathi AT, Ribrag V. Target Oncol. 2024 May;19(3):321-332

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin **Lymphomas**: Extended Follow-Up of a Phase I/II Study. Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, **Kim WS**, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, Cheah CY, Ma CY, Huang H, Kwan A, Wei MC, Yin S, Bartlett NL. J Clin Oncol. 2024 Jul 1;42(19):2250-2256

Lysine demethylase LSD1 is associated with stemness in EBV-positive B cell **lymphoma**. Kim JH, Park C, **Kim WS.** Sci Rep. 2024 Mar 21;14(1):6764.

Primary Nodal Epstein-Barr Virus-Positive T-Cell/NK-Cell **Lymphoma**: Real-World Experience. Choi DH, Yoon SE, Cho J, Kim SJ, **Kim WS.**Acta Haematol. 2024;147(6):625-633.

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell **Lymphoma**: Final Analysis of the Ro-CHOP Trial. Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas RO, Ysebaert L, Damaj GL, Guidez S, Pica GM, **Kim WS**, Lim ST, Andre M, Gutiérrez N, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Tucci A, Fogarty P, Farhat H, Abraham J, Abarah W, Belmecheri F, Ribrag V, Delfau-Larue MH, Cottereau AS, Itti E, Li J, Delarue R, de Leval L, Morschhauser F, Bachy E.J Clin Oncol. 2024 May 10;42(14):1612-1618

KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell **Lymphoma** Subtypes. Assatova B, Willim R, Trevisani C, Haskett G, Kariya KM, Chopra K, Park SR, Tolstorukov MY, McCabe SM, Duffy J, Louissaint A Jr, Huuhtanen J, Bhattacharya D, Mustjoki S, Koh MJ, Powers F, Morgan EA, Yang L, Pinckney B, Cotton MJ, Crabbe A, Ziemba JB, Brain I, Heavican-Foral TB, Iqbal J, Nemec R, Rider AB, Ford JG, Koh MJ, Scanlan N, Feith DJ, Loughran TP Jr, **Kim WS**, Choi J, Roels J,

Boehme L, Putteman T, Taghon T, Barnes JA, Johnson PC, Jacobsen ED, Greenberg SA, Weinstock DM, Jain S. Clin Cancer Res. 2024 Jun 3;30(11):2514-2530

mmune profiling of patients with extranodal natural killer/T cell **lymphoma** treated with daratumumab. Qing M, Zhou T, Perova T, Abraham Y, Sweeney C, Krevvata M, Zhang X, Qi M, Gao G, Kim TM, Yao M, Cho SG, Eom HS, Lim ST, Yeh SP, Kwong YL, Yoon DH, Kim JS, **Kim WS**, Zhou L, Attar R, Verona RI.Ann Hematol. 2024 Jun;103(6):1989-2001

Tumor-infiltrating T lymphocytes evaluated using digital image analysis predict the prognosis of patients with diffuse large B-cell **lymphoma**. Cho Y, Lee J, Han B, Yoon SE, Kim SJ, **Kim WS**, Cho J.J Pathol Transl Med. 2024 Jan;58(1):12-21

Feasibility of Circulating Tumor DNA Analysis in Patients with follicular **Lymphoma**.Yoon SE, Shin SH, Nam DK, Cho J, **Kim WS**, Kim SJ. Cancer Res Treat. 2024 Jul;56(3):920-935

Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies. Kim SJ, Yoon SE, **Kim WS.**Ann Lab Med. 2024 May 1;44(3):210-221.

Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. Matasar M, Bartlett NL, Shadman M, Budde LE, Flinn I, Gregory GP, Kim WS, Hess G, El-Sharkawi D, Diefenbach CS, Huang H, To I, Parreira J, Wu M, Kwan A, Assouline S. Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):240-253

A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell **lymphoma**. Lee YP, Jung YJ, Cho J, Ko YH, **Kim WS**, Kim SJ, Yoon SE.Blood Res. 2023 Dec 31;58(4):208-220

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell **lymphoma** (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, Zhang H, Mehta-Shah N, Ding K, Liu Y, Li Z, Zhang L, Zheng M, Jin J, Yang H, Shuang Y, Yoon DH, Gao S, Li W, Zhai Z, Zou L, Xi Y, Koh Y, Li F, Prince M, Zhou H, Lin L, Liu H, Allen P, Roncolato F, Yang Z, **Kim WS**, Zhu J.Lancet Oncol. 2024 Jan;25(1):117-125.

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell **lymphoma**. Yoon SE, Park S, Cho J, Ryu KJ, Yandava B, Lee S, Kim SJ, **Kim WS.** Front Oncol. 2023 Nov 16;13:1194315. doi:

Differences in mutational signature of diffuse large B-cell lymphomas according to the primary organ. Koh HH, Yoon SE, Kim SJ, Kim WS, Cho J. Cancer Med. 2023 Oct;12(19):19732-19743.

Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation. Kim SJ, Jo JC, Yoon DH, Yang DH, Yoon SE, Lee GW, Kong JH, Park Y, Kang KW, Lee HS, Oh SY, Shin HJ, Lee WS, Choi YS, Jeong SH, Kim MK, Kang HJ, Yi JH, Lim SN, Yhim HY, Do YR, Yun HJ, Eom HS, Lee MH, Suh C, Kim WS. Front Oncol. 2023 Aug 22;13:1230629.

Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell **lymphomas**. Song Y, Yoon DH, Yang H, Cao J, Ji D, Koh Y, Jing H, Eom H, Kwak J, Lee W, Lee J, Shin H, Jin J, Wang M, Yang Z, **Kim WS**, Zhu J. Ann Oncol. 2023 Sep 9:S0923-7534(23)00828-1.

Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma. Shin J, Lee JY, Lee GW, Kim WS, Park Y, Do YR, Kim DS, Kim KH, Choi YS, Byun JM, Hong J, Kim I, Yoon SS, Koh Y. Br J Haematol. 2023 Sep;202(6):e54-e57

Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma. Negoro E, Yamauchi T, Fukuhara N, Yamamoto K, Uchida T, Izutsu K, Maruyama D, Terui Y, Nakajima H, Ando K, Suehiro Y, Choi I, Kanemura N, Nakamura N,

Yamamoto G, Maeda Y, Shibayama H, Nagahama F, Sonehara Y, Nagai H, Tien HF, Kwong YL, Kim WS, Tobinai K. J Clin Exp Hematop. 2023;63(2):108-120.

A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B-cell lymphoma. Lee H, Yoon SE, Kim SJ, Kim WS, Cho J. Cancer Med. 2023 Aug;12(15):16359-16369

Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma. Lee YP, Yoon SE, Cho J, Ko YH, Oh D, Ahn YC, Kim WS, Kim SJ. Cancer Manag Res. 2023 Jun 5;15:463-474

Mutational characteristics of extranodal NK/T-cell **lymphoma** analyzed in relation to clinical prognostic indices.

Lee J, Yoon SE, Kim SJ, **Kim WS**, Cho J.Ann Hematol. 2024 Dec;103(12):5749-5757

Retrospective analysis of diagnosis and therapeutic strategies for patients with hepatosplenic T cell lymphoma. Jeon Y, Yoon SE, Cho J, Kim SJ, Kim WS. Ann Hematol. 2023 Jul;102(7):1867-1877

The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network. Hapgood G, Civallero M, Stepanishyna Y, Vose J, Cabrera ME, Advani RH, Pileri SA, Manni M, Horwitz SM, Foss FM, Hitz F, Radford J, Dlouhy I, Chiattone C, Kim WS, Skrypets T, Nagler A, Trotman J, Luminari S, Federico M. Blood Adv. 2023 Sep 12;7(17):5047-5054.

Allogeneic hematopoietic stem cell transplantation for NK/T-cell **lymphoma**: an international collaborative analysis. Berning P, Schmitz N, Ngoya M, Finel H, Boumendil A, Wang F, Huang XJ, Hermine O, Philippe L, Couronné L, Jaccard A, Liu D, Wu D, Reinhardt HC, Chalandon Y, Wagner-Drouet E, Kwon M, Zhang X, Carpenter B, Yakoub-Agha I, Wulf G, López-Jiménez J, Sanz J, Labussière-Wallet H, Shimoni A, Dreger P, Sureda A, **Kim WS**, Glass B.Leukemia. 2023 Jul;37(7):1511-1520.

Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study. Kim YR, Kim JS, Kim WS, Eom HS, Yang DH, Bae SH, Kim HJ, Lee JH, Oh SJ, Yoon SS, Kwak JY,

Choi CW, Kim MK, Oh SY, Kang HJ, Nam SH, Shim H, Park JS, Mun YC, Suh C; Korean Society of Hematology Lymphoma Working Party. Cancer Res Treat. 2023 Oct;55(4):1355-1362.

TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell **lymphoma** especially in elderly patients. Cho J, Kim E, Yoon SE, Kim SJ, **Kim WS.**Cancer. 2023 May 15;129(10):1502-1512.

TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell **lymphoma** especially in elderly patients. Cho J, Kim E, Yoon SE, Kim SJ, **Kim WS.**Cancer. 2023 May 15;129(10):1502-1512.

Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell **lymphoma**. Jeong SY, Yoon SE, Cho D, Kang ES, Cho J, **Kim WS**, Kim SJ.Front Oncol. 2023 Jan 19;12:1071281.

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis. Kim J, Cho J, Yoon SE, Kim WS, Kim SJ. Cancer Res Treat. 2023 Jul;55(3):1031-1047

In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas. Kim JJ, Kim HY, Choi Z, Hwang SY, Jeong H, Choi JR, Yoon SE, Kim WS, Kim SH, Kim HJ, Shin SY, Lee ST, Kim SJ. Front Oncol. 2023 Feb 10;

A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell **Lymphoma** Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Kim DY, Kim YR, Suh C, Yoon DH, Yang DH, Park Y, Eom HS, Lee JO, Kwak JY, Kang HJ, Hyun SY, Jo JC, Chang MH, Yoo KH, Lim SN, Shin HJ, **Kim WS**, Kim IH, Kim MK, Kim HJ, Lee WS, Mun YC, Kim JS.Am J Gastroenterol. 2023 Aug 1;118(8):1373-1380

The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell **lymphoma**. Yoon SE, Kang W, Choi S, Park Y, Chalita M, Kim H, Lee JH, Hyun DW, Ryu KJ, Sung H, Lee JY, Bae JW, **Kim WS**, Kim SJ .Blood. 2023 May 4;141(18):2224-2238.

Darinaparsin in patients with relapsed or refractory peripheral T-cell **lymphoma**: results of an Asian phase 2 study. **Kim WS**, Fukuhara N, Yoon DH, Yamamoto K, Uchida T, Negoro E, Izutsu K, Terui Y,

Nakajima H, Ando K, Suehiro Y, Kang HJ, Ko PS, Nagahama F, Sonehara Y, Nagai H, Tien HF, Kwong YL, Tobinai K.Blood Adv. 2023 Sep 12;7(17):4903-4912.

Comparison of histological and molecular features of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Lee J, Han JH, Lee CH, Park HS, Min SK, Lee H, Cho U, Yoon SE, Kim SJ, Kim WS, Cho J. Virchows Arch. 2023 May;482(5):849-858.

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H, Terui Y, Shin HJ, **Kim WS**, Cao J, Feng J, Eom HS, Kim TM, Tsai XC, Gau JP, Koh H, Zhang L, Song Y, Yang Y, Li W, Huang H, Ando K, Sharman JP, Sehn LH, Bu L, Wang X, Jiang Y, Hirata J, Lee C, Zhu J, Izutsu K.Blood. 2023 Apr 20;141(16):1971-1981.

Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin **Lymphoma**. Yoon DH, Koh Y, Jung M, Kwak JE, Shin EC, Hwang YK, **Kim WS.**Transplant Cell Ther. 2023 Apr;29(4):253.e1-253.e9.

Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell **Lymphoma**: A Korean Nationwide, Multicenter Prospective registry Study (CISL 1404). Cho H, Yoon DH, Shin DY, Koh Y, Yoon SS, Kim SJ, Do YR, Lee GW, Kwak JY, Park Y, Kim MK, Kang HJ, Yi JH, Yoo KH, Lee WS, Park BB, Jo JC, Eom HS, Kim HJ, Jeong SH, Won YW, Sohn BS, Kwon JH, Suh C, **Kim WS.**Cancer Res Treat. 2023 Apr;55(2):684-692.

Bendamustine Plus Rituximab for Mantle Cell **Lymphoma**: A Korean, Multicenter Retrospective Analysis. Yi JH, Kim SJ, Lee JO, Lee GW, Kwak JY, Eom HS, Jo JC, Choi YS, Oh SY, **Kim WS.** Anticancer Res. 2022 Dec;42(12):6083-6089.

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell **Lymphoma**. Kim SJ, Ryu KJ, Park B, Yoon SE, Cho J, Park Y, **Kim WS.**Cancers (Basel). 2022 Nov 16;14(22):5618.

A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with **lymphoma**.
Carlo-Stella C, Zinzani PL, Sureda A, Araújo L, Casasnovas O, Carpio C, Yeh SP, Bouabdallah K, Cartron G, **Kim WS**, Cordoba R, Koh Y, Re A, Alves D, Chamuleau M, Le Gouill S, López-Guillermo A, Moreira I, van der Poel MWM, Abbadessa G, Meng R, Ji R, Lépine L, Saleem R, Ribrag V.Hematol

Oncol. 2023 Feb;41(1):108-119.

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell **lymphoma**: phase IIb results. Rai S, **Kim WS**, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K.Haematologica. 2023 Mar 1;108(3):811-82

Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis. Lee YP, Lee MS, Yoon SE, Cho J, Bang YH, Shim JH, Kim WS, Kim SJ. J Oncol. 2022 Sep 26;2022:2263217. doi: 10.1155/2022/2263217. eCollection 2022.

Genomic profiling for clinical decision making in lymphoid neoplasms. de Leval L, Alizadeh AA, Bergsagel PL, Campo E, Davies A, Dogan A, Fitzgibbon J, Horwitz SM, Melnick AM, Morice WG, Morin RD, Nadel B, Pileri SA, Rosenquist R, Rossi D, Salaverria I, Steidl C, Treon SP, Zelenetz AD, Advani RH, Allen CE, Ansell SM, Chan WC, Cook JR, Cook LB, d'Amore F, Dirnhofer S, Dreyling M, Dunleavy K, Feldman AL, Fend F, Gaulard P, Ghia P, Gribben JG, Hermine O, Hodson DJ, Hsi ED, Inghirami G, Jaffe ES, Karube K, Kataoka K, Klapper W, Kim WS, King RL, Ko YH, LaCasce AS, Lenz G, Martin-Subero JI, Piris MA, Pittaluga S, Pasqualucci L, Quintanilla-Martinez L, Rodig SJ, Rosenwald A, Salles GA, San-Miguel J, Savage KJ, Sehn LH, Semenzato G, Staudt LM, Swerdlow SH, Tam CS, Trotman J, Vose JM, Weigert O, Wilson WH, Winter JN, Wu CJ, Zinzani PL, Zucca E, Bagg A, Scott DW. Blood. 2022 Nov 24;140(21):2193-2227

Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell **Lymphoma**. Yoon SE, Cho J, Kim YJ, Kim SJ, **Kim WS.**Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):e972-e980

EBV-associated NK and T-cell lymphoid neoplasms. Kimura H, de Leval L, Cai Q, **Kim WS.**Curr Opin Oncol. 2022 Sep 1;34(5):422-431.

Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell **Lymphoma** Entities in the Routine Clinical Practice. Amador C, Bouska A, Wright G, Weisenburger DD, Feldman AL, Greiner TC, Lone W, Heavican T, Smith L, Pileri S, Tabanelli V, Ott G, Rosenwald A, Savage KJ, Slack G, **Kim WS**, Hyeh Y, Li Y, Dong G, Song J, Ondrejka S, Cook JR, Barrionuevo C, Lim ST, Ong CK, Chapman J, Inghirami G, Raess PW, Bhagavathi S, Gould C, Blombery P, Jaffe E, Morris SW, Rimsza LM, Vose JM, Staudt L, Chan WC, Iqbal J.J Clin Oncol. 2022 Dec 20;40(36):4261-4275.

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ; ECHELON-1 Study Group. N Engl J Med. 2022 Jul 28;387(4):310-320.

A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell **lymphoma** patients from an international cohort. Lim JQ, Huang D, Chan JY, Laurensia Y, Wong EKY, Cheah DMZ, Chia BKH, Chuang WY, Kuo MC, Su YJ, Cai QQ, Feng Y, Rao H, Feng LN, Wei PP, Chen JR, Han BW, Lin GW, Cai J, Fang Y, Tan J, Hong H, Liu Y, Zhang F, Li W, Poon MLM, Ng SB, Jeyasekharan A, Ha JCH, Khoo LP, Chin ST, Pang WL, Kee R, Cheng CL, Grigoropoulos NF, Tang T, Tao M, Farid M, Puan KJ, Xiong J, Zhao WL, Khor CC, Hwang W, **Kim WS**, Campo E, Tan P, Teh BT, Chng WJ, Rötzschke O, Tousseyn T, Huang HQ, Rozen S, Lim ST, Shih LY, Bei JX, Ong CK.Am J Hematol. 2022 Sep;97(9):1159-1169

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d'Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD.
Blood. 2022 Sep 15;140(11):1229-1253.

Comprehensive comparison of international prognostic indexes for follicular helper T-cell **lymphoma**. Lee YP, Yoon SE, Cho J, Ko YH, Jo H, Kim SJ, **Kim WS.**Ann Hematol. 2022 Jul;101(7):1535-1543.

CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell **lymphoma** and associated with 18q21 gain. Cho J, Yoon SE, Kim SJ, Ko YH, **Kim WS.**Blood Adv. 2022 Dec 27;6(24):6120-6130.

Outcomes in Refractory Diffuse Large B-Cell **Lymphoma**: Results from Two Prospective Korean Cohorts. Yi JH, Jeong SH, Kim SJ, Yoon DH, Kang HJ, Koh Y, Kim JS, Lee WS, Yang DH, Do YR, Kim

MK, Yoo KH, Choi YS, Yun WJ, Park Y, Jo JC, Eom HS, Kwak JY, Shin HJ, Park BB, Yi SY, Kwon JH, Oh SY, Kim HJ, Sohn BS, Won JH, Hong DS, Lee HS, Lee GW, Suh C, **Kim WS.**Cancer Res Treat. 2023 Jan;55(1):325-333.

Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL). Kim KH, Lee JH, Lee M, Kim HG, Do YR, Park Y, Oh SY, Shin HJ, Kim WS, Park SK, Kong JH, Park MR, Yang DH, Kwak JY, Kang HJ, Mun YC, Won JH. Cancer Res Treat. 2023 Jan;55(1):304-313.

A New Prognostic Index for Extranodal Natural Killer/T-Cell **Lymphoma**:Incorporation of Serum β-2 Microglobulin to PINK. Kang S, Cho H, Kim S, Lee K, Kang EH, Park JS, Lee YS, Park CS, Go H, Huh J, Ryu JS, Lee SW, Kim SJ, **Kim WS**, Yoon SE, Ko YH, Suh C.Cancer Res Treat. 2023 Jan;55(1):314-324.

Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin **lymphoma**. Bang YH, Shim JH, Ryu KJ, Kim YJ, Choi ME, Yoon SE, Cho J, Park B, Park WY, **Kim WS**, Kim SJ. J Cancer. 2022 Feb 21;13(5):1388-1397

Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell **Lymphomas**. Kim SJ, Kim YJ, Yoon SE, Ryu KJ, Park B, Park D, Cho D, Kim HY, Cho J, Ko YH, Park WY, **Kim WS.**Cancer Res Treat. 2023 Jan;55(1):291-303.

Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS **lymphoma** treated with R-MVP: real-world data from a retrospective single-center analysis. Yoon SE, Jo H, Kang ES, Cho D, Cho J, **Kim WS**, Kim SJ.Bone Marrow Transplant. 2022 Apr;57(4):641-648.

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell **Lymphoma** Treated with R-CHOP: A Prospective Cohort Study. Jeong SH, Kim SJ, Yoon DH, Park Y, Kang HJ, Koh Y, Lee GW, Lee WS, Yang DH, Do YR, Kim MK, Yoo KH, Choi YS, Yun HJ, Yi JH, Jo JC, Eom HS, Kwak JY, Shin HJ, Park BB, Hyun SY,

Yi SY, Kwon JH, Oh SY, Kim HJ, Sohn BS, Won JH, Kim SH, Lee HS, Suh C, **Kim WS.** Cancer Res Treat. 2022 Oct;54(4):1268-1277.

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell **lymphoma**. Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, **Kim WS**, Feldman T, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T.Ann Oncol. 2022 Mar;33(3):288-298.

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell **Lymphomas**: Phase I Dose-Escalation Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, **Kim WS**, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL.J Clin Oncol. 2022 Feb 10;40(5):481-491
Risk of non-Hodgkin **lymphoma** in breast cancer survivors: a nationwide cohort study.
Kang D, Yoon SE, Shin D, Lee J, Hong YS, Lee SK, Lee JE, Park YH, Ahn JS, Guallar E, **Kim WS**, Lee J, Kim SJ, Cho J.Blood Cancer J. 2021 Dec 14;11(12):200.

Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system **lymphoma**.
Kim N, Lim DH, Yoon SE, Kim SJ, **Kim WS.**J Neurooncol. 2022 Jan;156(2):307-316.
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell **Lymphoma**: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, Damaj G, Guidez S, Pica GM, **Kim WS**, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue MH, de Leval L, Meignan M, Li J, Morschhauser F, Delarue R.J Clin Oncol. 2022 Jan 20;40(3):242-251.
Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell **lymphoma** not otherwise specified.
Kim HD, Cho H, Sohn BS, Park CS, Huh J, Ryu JS, Lee SW, Yoon SE, Kim SJ, Ko YH, **Kim WS**, Suh C.Leuk Lymphoma. 2022 Jan;63(1):124-130.
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular **Lymphoma**: Final Results of a Randomized Phase III Study. Kwak LW, Sancho JM, Cho SG,

Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Menne T, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Ogura M, **Kim WS**, Lee SJ, Kim SH, Ahn KY, Buske C.Clin Lymphoma Myeloma Leuk. 2022 Feb;22(2):89-97

PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Lee YH, Lee HJ, Kim HC, Lee Y, Nam SK, Hupperetz C, Ma JSY, Wang X, Singer O, **Kim WS**, Kim SJ, Koh Y, Jung I, Kim CH.Mol Ther. 2022 Feb 2;30(2):579-592.

Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell **Lymphoma**. Lim CH, Yoon SE, **Kim WS**, Lee KH, Kim SJ.Cancer Manag Res. 2021 Sep 21;13:7289-7297.

Comparison of first-line treatments of peripheral T-cell **lymphoma** according to regimen: A systematic review and meta-analysis. Kim J, Cho J, Byeon S, **Kim WS**, Kim SJ.Hematol Oncol. 2021 Dec;39(5):664-673.

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular **lymphoma**: a randomized phase 3 study. Buske C, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Kwak L, **Kim WS**, Lee S, Kim S, Ahn K, Ogura M.Blood Adv. 2021 Sep 14;5(17):3354-3361.

Comparison of tumor mutation burden of 300 various non-Hodgkin **lymphomas** using panel based massively parallel sequencing. Cho J, Yoon SE, Kim SJ, Ko YH, **Kim WS.**BMC Cancer. 2021 Aug 30;21(1):972. doi: 10.1186/s12885-021-08695-7

Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system **lymphoma**: a comparative analysis of whole-brain radiation therapy versus no radiation therapy. Kim N, Lim DH, Yoon SE, Kim SJ, **Kim WS.**J Neurooncol. 2021 Sep;154(2):207-217.

Comprehensive analysis of peripheral T-cell and natural killer/T-cell **lymphoma** in Asian patients: A multinational, multicenter, prospective registry study in Asia. Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, Koh Y, Kang KW, Lee HS, Tay KKW, Lim ST, Poon M, Irawan C, Zhao W, Do YR, Lee MH, Ng SC, Lee WS, Guo Y, Zhang H, Kang HJ, Yun HJ, Kim HJ, Lung DTC, Kwak JY, Han JJ, Mun YC, Oh SY, Shim H, Kwon JH, Sohn BS, Park SK, Jo JC, Ko YH, Jun Z, **Kim WS.**Lancet Reg Health West Pac. 2021 Mar 22;10:100126. doi: 10.1016/j.lanwpc.2021.1

Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System **Lymphoma**. Yoon SE, Kim YJ, Shim JH, Park D, Cho J, Ko YH, Park WY, Mun YC, Lee KE, Cho D, **Kim WS**, Kim SJ.Cancer Res Treat. 2022 Apr;54(2):597-612

Autologous EBV-specfic T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Kim WS, Oki Y, Kim SJ, Yoon SE, Ardeshna KM, Lin Y, Ruan J, Porcu P, Brammer JE, Jacobsen ED, Yoon DH, Suh C, Suarez F, Radford J, Budde LE, Kim JS, Bachy E, Lee HJ, Bollard CM, Jaccard A, Kang HJ, Inman S, Murray M, Combs KE, Lee DY, Advani R, Gunter KC, Rooney CM, Heslop HE. Ann Hematol. 2021 Oct;100(10):2529-2539. doi: 10.1007/s00277-021-04558-0. Epub 2021 Jul 24

Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. Lee YP, Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, Koh YI, Kang KW, Lee HS, Wei KTK, Lim ST, Poon M, Irawan C, Zhao W, Do YR, Lee MH, Ng SC, Lee WS, Guo Y, Zhang H, Kang HJ, Yun HJ, Kim HJ, Lung DTC, Kwak JY, Han JJ, Mun YC, Oh SY, Shim H, Kwon JH, Sohn BS, Park SK, Jo JC, Ko YH, Jun Z, Kim WS.Int J Hematol. 2021 Sep;114(3):355-362. doi: 10.1007/s12185-021-03179-7. Epub 2021 Jul 24.PMID: 34302593

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, Shustov AR, Horwitz SM, Hitz F, Cabrera ME, Dlouhy I, Vassallo J, Pileri SA, Inghirami G, Montoto S, Vitolo U, Radford J, Vose JM, Federico M. Blood. 2021 Jul 22;138(3):213-220. doi: 10.1182/blood.2020010387.

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, Feldman T, Tuscano J, Savage KJ, Oki Y, Grigg A, Pocock C, Dlugosz-Danecka M, Fenton K, Forero-Torres A, Liu R, Jolin H, Gautam A, Gallamini A. Haematologica. 2022 May 1;107(5):1086-1094. doi: 10.3324/haematol.2021.27843

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, Kim WS, Rule S, Atwal SK, Wei R, Novotny W, Huang J, Wang M, Trotman J. Blood Adv. 2021 Jun 22;5(12):2577-2585. doi: 10.1182/bloodadvances.202000407

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma. Lee YP, Hong JY, Yoon SE, Cho J, Shim JH, Bang Y, Kim WS, Kim SJ. Cancer Manag Res. 2021 May 28;13:4241-4250. doi: 10.2147/CMAR.S309092. eCollection 2021

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Straus DJ, Długosz-Danecka M, Connors JM, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J.Lancet Haematol. 2021 Jun;8(6):e410-e421. doi: 10.1016/S2352-3026(21)00102-2.

EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma. Lee JY, Kim JH, Bang H, Cho J, Ko YH, Kim SJ, Kim WS. Sci Rep. 2021 May 14;11(1):10342. doi: 10.1038/s41598-021-89754-8

Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas. Yoon SE, Cho J, Kim YJ, Ko YH, Park WY, Kim SJ, Kim WS.Exp Hematol Oncol. 2021 May 14;10(1):33. doi: 10.1186/s40164-021-00224-3.

Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation. Park YJ, Hyun SH, Moon SH, Lee KH, Min BH, Lee JH, Kim WS, Kim SJ, Choi JY. Sci Rep. 2021 Apr 29;11(1):9243. doi: 10.1038/s41598-021-88815-2.

Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months. Yoon SE, Cho J, Kim WS, Kim SJ. J Cancer. 2021 Mar 5;12(9):2488-2497. doi: 10.7150/jca.54434. eCollection 2021

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Lee B, Lee H, Cho J, Yoon SE, Kim SJ, Park WY, Kim WS, Ko YH. Front Oncol. 2021 Mar 11;11:628807. doi: 10.3389/fonc.2021.628807. eCollection 2021.

MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma. Cho YA, Hyeon J, Lee H, Cho J, Kim SJ, Kim WS, Ko YH. Hum Pathol. 2021 Jul;113:9-19. doi: 10.1016/j.humpath.2021.03.006. Epub 2021 Mar 23

Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications. Kim JH, Kim WS, Park C. Antiviral Res. 2021 May;189:105063. doi: 10.1016/j.antiviral.2021.105063. Epub 2021 Mar 16.

Metabolic activity of extranodal NK/T cell lymphoma on 18F-FDG PET/CT according to immune subtyping. Lim CH, Yoon SE, Kim SJ, Cho J, Ko YH, Lee KH, Kim WS. Sci Rep. 2021 Mar 15;11(1):5879. doi: 10.1038/s41598-021-85332-0

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. Yi JH, Kim SJ, Yoon DH, Suh C, Chang MH, Yang DH, Jo JC, Hyun SY, Eom HS, Lee JO, Kwon JH, Han SH, Lee SS, Kwak JY, Kim SH, Kim DS, Lee JH, Oh SY, Ryoo HM, Kim HJ, Kim WS. Cancer Commun (Lond). 2021 Mar;41(3):275-278.

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. Huang H, Zhu J, Yao M, Kim TM, Yoon DH, Cho SG, Eom HS, Lim ST, Yeh SP, Song Y, Kwong YL, Kim JS, Jin J, Shi Y, Kim H, Qing M, Zhou T, Gao G, Dong Z, Qi M, Kim WS.

J Hematol Oncol. 2021 Feb 15;14(1):25. doi: 10.1186/s13045-020-01020-y

Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial. Yhim HY, Kim T, Kim SJ, Shin HJ, Koh Y, Kim JS, Park J, Park GS, Kim WS, Moon JH, Yang DH. Ann Oncol. 2021 Apr;32(4):552-559

The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma. Kang JH, Lee SH, Lee J, Choi M, Cho J, Kim SJ, Kim WS, Ko YH, Yoo HY. BMC Cancer. 2021 Jan 19;21(1):82.

Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial. Yhim HY, Kim T, Kim SJ, Shin HJ, Koh Y, Kim JS, Park J, Park GS, Kim WS, Moon JH, Yang DH. Ann Oncol. 2020 Dec 25:S0923-7534(20)43215-6

Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. Song GY, Yoon DH, Suh C, Moon JH, Baek DW, Kim JS, Lee GW, Yi JH, Park Y, Jung KS, Kim SJ, Yang DH, Kim WS. Bone Marrow Transplant. 2020 Dec 4. doi: 10.1038/s41409-020-01160-2

Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma. Ryu KJ, Lee JY, Choi ME, Yoon SE, Cho J, Ko YH, Shim JH, Kim WS, Park C, Kim SJ. Cancers (Basel). 2020 Nov 27;12(12):

A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. Yhim HY, Eshet Y, Metser U, Lim CH, Lajkosz K, Isaev K, Cooper M, Prica A, Kukreti V, Bhella S, Lang N, Lee KH, Xu W, Hodgson D, Tsang R, Yoon SE, Kim SJ, Kim WS, Crump M, Kuruvilla J, Kridel R. Blood Adv. 2020 Nov 24;4(22):5762-5771

Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea. Ogura M, Kim WS, Uchida T, Uike N, Suehiro Y, Ishizawa K, Nagai H, Nagahama F, Sonehara Y, Tobinai K. Jpn J Clin Oncol. 2020 Oct 14:hyaa177. doi: 10.1093

First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using mmunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. Yhim HY, Yoon DH, Kim SJ, Yang DH, Eom HS, Kim KH, Park Y, Kim JS, Kim HJ, Suh C, Kim WS, Kwak JY. Cancers (Basel). 2020 Aug 6;12(8):2192. doi: 10.3390

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. Kim SJ, Lim JQ, Laurensia Y, Cho J, Yoon SE, Lee JY, Ryu KJ, Ko YH, Koh Y, Cho D, Lim ST, Enemark MB, D'Amore F, Bjerre M, Ong CK, Kim WS. Blood. 2020 Dec 10;136(24):2754-2763

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Lim JQ, Huang D, Tang T, Tan D, Laurensia Y, Peng RJ, Wong EKY, Cheah DMZ, Chia BKH, Iqbal J, Grigoropoulos NF, Nairismägi ML, Ng CCY, Rajasegaran V, Hong H, Kim SJ, Cho J, Tse E, Mow B, Cai QC, Poon LM, Cai QQ, Tan J, Chan JY, Lim JX, Goh YT, Phipps C, Rötzschke O, Cheng CL, Ha JCH, Khoo LP, Loh YSM, Au-Yeung R, Chan TS, Kwong YL, Hwang W, Kim WS, Bei JX, Lin T, Ong CK, Lim ST. Leukemia. 2020 Dec;34(12):3413-3419

Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study. Hur JY, Yoon SE, Kim SJ, Kim WS. Blood Res. 2020 Jun 30;55(2):85-90. doi: 10.5045/br.2020.2020014.

Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Kim H, Jeong H, Yamaguchi M, Sohn I, Yoon SE, Byeon S, Hur JY, Koh Y, Yoon SS, Kim EJ, Oguchi M, Miyazaki K, Taguchi S, Yoon DH, Cho J, Ko YH, Kim SJ, Suzuki R, Kim WS. Blood. 2020 Jun 25:blood.2020005026. doi: 10.1182/blood.2020005026

Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. Jang JH, Kim Y, Park S, Kim K, Kim SJ, Kim WS, Jung CW, Lee J, Lee SH. PLoS Med. 2020 Jun 8;17(6):e1003091. doi: 10.1371/journal.pmed.1003091. eCollection 2020 Jun.

Treatment with Intravenous Busulfan, Melphalan, and Etoposide (BuME) followed by Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from the

Consortium for Improving Survival of Lymphoma (CISL). Kim KH, Kim WS, Kim SJ, Yoon DH, Suh C, Kang HJ, Choi CW, Lee HS, Bae SH, Park J, Kyung Park E, Kwak JY, Lee MH, Kang BW, Park SK, Won JH; Korean Society of Hematology Lymphoma Working Party. Transpl Int. 2020 Jun 1. doi: 10.1111/tri.13664

Survival outcomes for extranodal natural-killer T-cell lymphoma - Authors' reply. Fox CP, Civallero M, Federico M, Kim WS. Lancet Haematol. 2020 Jun;7(6):e442. doi: 10.1016/S2352-3026(20)30152-

A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study. Yoon SE, Eun Y, Huh K, Chung CR, Yoo IY, Cho J, Cho D, Ko YH, Park S, Kim WS, Kim SJ. Ann Hematol. 2020 May 21. doi: 10.1007/s00277-020-04083-6

A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis. Yoon SE, Kim SJ, Yoon DH, Koh Y, Mun YC, Do YR, Choi YS, Yang DH, Kim MK, Lee GW, Suh C, Ko YH, Kim WS. Ann Hematol. 2020 Jun;99(6):1283-1291. doi: 10.1007/s00277-020-04005-6. Epub 2020 Apr 24.

Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas. Hur JY, Kim YJ, Yoon SE, Son DS, Park WY, Kim SJ, Park D, Kim WS. Ann Hematol. 2020 Jun;99(6):1293-1302. doi: 10.1007/s00277-020-04008-3.

Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified. Cho I, Yoon N, Hyeon J, Sim J, Yoo HY, Kim SJ, Kim WS, Ko YH. Appl Immunohistochem Mol Morphol. 2020 Apr 13. doi: 10.1097/PAI.0000000000000843.

Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. Yoon DH, Cao J, Chen TY, Izutsu K, Kim SJ, Kwong YL, Lin TY, Thye LS, Xu B, Yang DH, Kim WS. J Hematol Oncol. 2020 Mar 17;13(1):21. doi: 10.1186/s13045-020-00855-9.

Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Yi JH, Yoon SE, Ryu KJ, Ko YH, Kim WS, Kim SJ. Cytokine. 2020 Mar 2;129:155048. doi: 10.1016/j.cyto.2020.155048. Online ahead of print.

Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk. Witalis M, Chang J, Zhong MC, Bouklouch Y, Panneton V, Li J, Buch T, Kim SJ, Kim WS, Ko YH, Veillette A, Suh WK. lood Adv. 2020 Mar 10;4(5):868-879. doi: 10.1182/bloodadvances.2019001114.

Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Fox CP, Civallero M, Ko YH, Manni M, Skrypets T, Pileri S, Kim SJ, Cabrera ME, Shustov AR, Chiattone CS, Horwitz SM, Dlouhy I, Spina M, Hitz F, Montoto S, Nagler A, Martinez V, De Souza CA, Fernandez-Alvarez R, Ballova V, Gabús R, Inghirami G, Federico M, Kim WS. Lancet Haematol. 2020 Apr;7(4):e284-e294. doi: 10.1016/S2352-3026(19)30283-2. Epub 2020 Feb 24.

A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group. Hong H, Li Y, Lim ST, Liang C, Huang H, Yi P, Wu T, Du X, Zhang M, Wang J, Zhu J, Liu T, Meng F, Wu G, Guo Y, Zhu Y, Zhao W, Jin J, Li J, Deng Y, Gu K, Wu X, Ke X, Xie D, Lin D, Peng Z, Wu J, Liu Q, Kim WS, Lin T. Leukemia. 2020 Feb 17. doi: 10.1038/s41375-020-0740-1. Online ahead of print.

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. Cho I, Lee H, Yoon SE, Ryu KJ, Ko YH, Kim WS, Kim SJ. BMC Cancer. 2020 Feb 13;20(1):120. doi: 10.1186/s12885-020-6612-2.

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A. Blood. 2020 Mar 5;135(10):735-742. doi: 10.1182/blood.2019003127.

A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma. Won YW, Lee H, Eom HS, Kim JS, Suh C, Yoon DH, Hong JY, Kang HJ, Lee JH, Kim WS, Kim SJ, Lee WS, Chang MH, Do YR, Yi JH, Kim I, Won JH, Kim K, Oh SY, Jo JC. Ann Hematol. 2020 Feb;99(2):255-264. doi: 10.1007/s00277-019-03891-9. Epub 2020 Jan 2.

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. Hong JY, Yoon DH, Yoon SE, Kim SJ, Lee HS, Eom HS, Lee HW, Shin DY, Koh Y, Yoon SS, Jo JC, Kim JS, Kim SJ, Cho SH, Lee WS, Won JH, Kim WS, Suh C. Sci Rep. 2019 Dec 30;9(1):20302. doi: 10.1038/s41598-019-56891-0.

Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lin GW, Xu C, Chen K, Huang HQ, Chen J, Song B, Chan JKC, Li W, Liu W, Shih LY, Chuang WY, Kim WS, Tan W, Peng RJ, Laurensia Y, Cheah DMZ, Huang D, Cheng CL,

Su YJ, Tan SY, Ng SB, Tang TPL, Han K, Wang VY, Jia WH, Pei Z, Li YJ, Gao S, Shi Y, Hu Z, Zhang F, Zhang B, Zeng YX, Shen H, He L, Ong CK, Lim ST, Chanock S, Kwong YL, Lin D, Rothman N, Khor CC, Lan Q, Bei JX; International NKTCL Working Group. Lancet Oncol. 2020 Feb;21(2):306-316. doi: 10.1016/S1470-2045(19)30799-5. Epub 2019 Dec 23.

Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim WS, Nagler A, Dimou M, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Munoz J, Rodrigues L, Hiemeyer F, Miriyala A, Garcia-Vargas J, Childs BH, Zinzani PL. Am J Hematol. 2019 Dec 23. doi: 10.1002/ajh.25711.

Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system. Yoon SE, Kim WS, Kim SJ. Korean J Intern Med. 2020 Jul;35(4):946-956. doi: 10.3904/kjim.2018.396. Epub 2019 Nov 25.

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. Foss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Montoto S, Chiattone C, Moskowitz A, Spina M, Cesaretti M, Biasoli I, Federico M. Am J Hematol. 2020 Feb;95(2):151-155. doi: 10.1002/ajh.25674. Epub 2019 Nov 25.

Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. Kim SJ, Yoon DH, Kang HJ, Hong JY, Lee HS, Oh SY, Shin HJ, Kong JH, Yi JH, Sakamoto K, Ko YH, Huh J, Lee SS, Takeuchi K, Shin DY, Suh C, Kim WS. BMC Cancer. 2019 Nov 10;19(1):1080. doi: 10.1186/s12885-019-6303-z.

Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016: An observational study. Sim J, Takayama T, Cho J, Kim SJ, Kim WS, Ree HJ, Ko YH. Medicine (Baltimore). 2019 Nov;98(45):e17641. doi:

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6.

Impact of fear of cancer recurrence on survival among lymphoma patients. Kim SJ, Kang D, Kim IR, Yoon SE, Kim WS, Butow PN, Guallar E, Cho J.Psychooncology. 2020 Feb;29(2):364-372. doi: 10.1002/pon.5265. Epub 2020 Jan 6.

Cho J, Kim SJ, Park WY, Kim J, Woo J, Kim G, Yoon SE, Ko YH, Kim WS. Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression. Mod Pathol. 2020 Apr;33(4):603-615. doi: 10.1038/s41379-019-0392-8. Epub 2019 Oct 25.

Tan KM, Chia B, Lim JQ, Khoo LP, Cheng CL, Tan L, Poon E, Somasundaram N, Farid M, Tang TPL, Tao M, Cheah DMZ, Laurensia Y, Pang JWL, Song T, Tan J, Huang D, Kim SJ, Kim WS, Ong CK, Lim ST, Chan JY. A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study. Sci Rep. 2019 Oct 18;9(1):14961. doi: 10.1038/s41598-019-51522-0.

Oh SY, Kim WS, Kim JS, Kim SJ, Yoon DH, Yang DH, Lee WS, Kim HJ, Yhim HY, Jeong SH, Won JH, Lee S, Kong JH, Lim SN, Ji JH, Kwon KA, Lee GW, Lee JH, Lee HS, Shin HJ, Suh C. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study Cancer Commun (Lond). 2019 Oct 16;39(1):58. doi: 10.1186/s40880-019-0403-7.

Kim JH, Kim WS, Park C. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma BMC Cancer. 2019 Oct 10;19(1):936. doi: 10.1186/s12885-019-6057-7.

Yi JH, Lee GW, Do YR, Jung HR, Hong JY, Yoon DH, Suh C, Choi YS, Yi SY, Sohn BS, Kim BS, Oh SY, Park J, Jo JC, Lee SS, Oh YH, Kim SJ, Kim WS. Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma Ann Hematol. 2019 Nov;98(11):2541-2550. doi: 10.1007/s00277-019-03791-y. Epub 2019 Sep 6.

Kim SJ, Yoon DH, Kim JS, Kang HJ, Lee HW, Eom HS, Hong JY, Cho J, Ko YH, Huh J, Yang WI, Park WS, Lee SS, Suh C, Kim WS. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. Cancer Res Treat. 2020 Apr;52(2):374-387. doi: 10.4143/crt.2019.198. Epub 2019 Aug 13.

O'Connor OA, Marchi E, Volinn W, Shi J, Mehrling T, Kim WS. Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study. JNCI Cancer Spectr. 2018 Dec 1;2(4):pky038. doi: 10.1093/jncics/pky038. eCollection 2018 Oct.

Huh SJ, Oh SY, Lee S, Lee JH, Kim SH, Lee GW, Kim SJ, Kim WS, Lee HS, Jo JC, Kim MJ, Kwon JH, Kim HJ. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma

(PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. Int J Hematol. 2019 Oct;110(4):438-446. doi: 10.1007/s12185-019-02693-z. Epub 2019 Jun 27. PMID: 31250282

Park BB, Kim WS, Suh C, Hong JY, Yang DH, Lee WS, Do YR, Koh YI, Won JH, Kim MK, Jo JC, Hyun SY, Kim JA, Oh YH, Lee SS. A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). Leuk Lymphoma. 2019 Dec;60(13):3251-3257. doi: 10.1080/10428194.2019.1622100. Epub 2019 Jun 6.

Song HY, Kim HM, Mushtaq S, Kim WS, Kim YJ, Lim ST, Byun EB. Gamma-Irradiated Chrysin Improves Anticancer Activity in HT-29 Colon Cancer Cells Through Mitochondria-Related Pathway J Med Food. 2019 Jul;22(7):713-721. doi: 10.1089/jmf.2018.4320. Epub 2019 Jun 3.

Park JH, Bae TH, Kim WS, Kim HK. Anaplastic Large Cell Lymphoma Mimicking Cellulitis: A Case Report Int J Low Extrem Wounds. 2019 Jun;18(2):208-211. doi: 10.1177/1534734619843704. Epub 2019 Apr 30.

Kim HK, Kang W, Sinn DH, Lee JH, Kim WS, Kim SJ. Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance. Korean J Intern Med. 2020 Jan;35(1):194-204. doi: 10.3904/kjim.2018.196. Epub 2019 Apr 4.

Shin SH, Kim YJ, Lee D, Cho D, Ko YH, Cho J, Park WY, Park D, Kim SJ, Kim WS. Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes. Leuk Lymphoma. 2019 Sep;60(9):2237-2246. doi: 10.1080/10428194.2019.1573998. Epub 2019 Feb 18.

Shin J, Ko YH, Oh SY, Yoon DH, Lee JO, Kim JS, Park Y, Shin HJ, Kim SJ, Won JH, Yoon SS, Kim WS, Koh Y; Consortium for Improving Survival of Lymphoma investigators. Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. Cancer Res Treat. 2019 Oct;51(4):1302-1312. doi: 10.4143/crt.2018.555. Epub 2019 Feb 14. PMID: 30764603 Free PMC article.

O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single

Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J Clin Oncol. 2019 Mar 10;37(8):613-623. doi: 10.1200/JCO.18.00899. Epub 2019 Feb 1.

Park S, Jo JC, Do YR, Yang DH, Lim SN, Lee WS, Kim WS, Lee HS, Hong DS, Kim HJ, Shin HJ. Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):149-156. doi: 10.1016/j.clml.2018.11.003. Epub 2018 Nov 12.

Kim SJ, Yoon SE, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review J Hematol Oncol. 2018 Dec 20;11(1):140. doi: 10.1186/s13045-018-0687-0.

Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4.

Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Coiffier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial Lancet Haematol. 2018 Nov;5(11):e543-e553. doi: 10.1016/S2352-3026(18)30157-1.

Kim SJ, Shu C, Ryu KJ, Kang D, Cho J, Ko YH, Lee SY, Guallar E, Zhao W, Kim WS. Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma Cancer Sci. 2018 Dec;109(12):3971-3980. doi: 10.1111/cas.13844. Epub 2018 Nov 28.

Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044.

Yi JH, Ryu KJ, Ko YH, Kim WS, Kim SJ. Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma Cytokine. 2019 Jan;113:371-379

Hong J, Cho J, Ko YH, Kim SJ, Kim WS. Validation of the Marginal Zone Lymphoma International Prognostic Index Ann Hematol. 2019 Feb;98(2):457-464. doi: 10.1007/s00277-018-3516-1

.Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Coiffier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial Lancet Haematol. 2018 Nov;5(11):e543-e553.

Kim SJ, Shu C, Ryu KJ, Kang D, Cho J, Ko YH, Lee SY, Guallar E, Zhao W, Kim WS. Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma Cancer Sci. 2018 Oct 21. doi: 10.1111/cas.13844

Yi JH, Ryu KJ, Ko YH, Kim WS, Kim SJ. Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma Cytokine. 2018 Oct 13. pii: S1043-4666(18)30397-1. doi: 10.1016/j.cyto.2018.10.009

Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy Blood. 2018 Oct 19. pii: blood-2018-04-848044. doi: 10.1182/blood-2018-04-848044

Jeong SH, Song HN, Park JS, Yang DH, Koh Y, Yoon SS, Lee HW, Eom HS, Won JH, Kim WS, Kim SJ. Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation Biol Blood Marrow Transplant. 2018 Jul 29. pii: S1083-8791(18)30423-3. doi:

Hong J, Cho J, Ko YH, Kim SJ, Kim WS. Validation of the Marginal Zone Lymphoma International Prognostic Index Ann Hematol. 2018 Oct 11. doi: 10.1007/s00277-018-3516-1

Yhim HY, Park Y, Han YH, Kim S, Kang SR, Moon JH, Jeong JH, Shin HJ, Kim K, Choi YS, Kim K, Kim MK, Kong E, Kim DS, Eo JS, Lee JH, Kang DY, Lee WS, Lee SM, Do YR, Ham JS, Kim SJ, Kim WS, Choi JY, Yang DH, Kwak JY. A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2274-2284. doi: 10.1007/s00259-018-4093-

Kim SJ, Hyeon J, Cho I, Ko YH, Kim WS. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus–Positive and –Negative Relapsed or Refractory Non-Hodgkin Lymphomas Cancer Res Treat. 2018 Jul 20. doi: 10.4143/crt.2018.191

Lim SW, Ryu KJ, Lee H, Ko YH, Kim WS, Kim SJ. Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma Leuk Lymphoma. 2018 Jul 6:1-9. doi: 10.1080/10428194.2018.1480772

Oh SY, Kim WS, Kang HJ, Lee JH, Huh SJ, Kim SJ, Yoon DH, Hong JY, Lee WS, Kim HJ, Won JH, Park BB, Lee SI, Suh C. Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study Ann Hematol. 2018 Oct;97(10):1851-1857

Hyeon J, Lee B, Shin SH, Yoo HY, Kim SJ, Kim WS, Park WY, Ko YH. Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement Mod Pathol. 2018 Sep;31(9):1418-1428. doi: 10.1038/s41379-018-0064-0

Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target Nat Commun. 2018 Apr 19;9(1):1567.

Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, Pileri S, Ko YH, Cabrera ME, Horwitz S, Kim WS, Shustov A, Foss FM, Nagler A, Carson K, Pinter-Brown LC, Montoto S, Spina M, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Gabus R, Vose JM, Advani RH; T cell Project Network. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. 2018 Jun;181(6):760-769

Cho J, Kim SJ, Park S, Yoo KH, Ki CS, Ko Y, Kim WS. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma Ann Hematol. 2018 Aug;97(8):1427-1436

Hong JY, Yoon DH, Suh C, Kim WS, Kim SJ, Jo JC, Kim JS, Lee WS, Oh SY, Park Y, Kim SY, Lee MH, Lee HS, Do YR. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis Ann Hematol. 2018 Aug;97(8):1437-1443

Yamaguchi M, Suzuki R, Kim SJ, Ko YH, Oguchi M, Asano N, Miyazaki K, Terui Y, Kubota N, Maeda T, Kobayashi Y, Amaki J, Soejima T, Saito B, Shimoda E, Fukuhara N, Tsukamoto N, Shimada K, Choi I, Utsumi T, Ejima Y, Kim WS, Katayama N. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy Cancer Sci. 2018 Jun;109(6):2056-2062

Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Martinez V, Montoto S, Chiattone C, Moskowitz A, Spina M, Biasoli I, Manni M, Federico M; International T-cell Project Network. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project Haematologica. 2018 Jul;103(7):1191-1197

Cho H, Yoon DH, Kim KP, Bae KS, Kim WS, Eom HS, Kim JS, Hong JY, Kim SJ, Lee H, Kim SJ, Suh C. Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy Invest New Drugs. 2018 Oct;36(5):877-885

Kim JH, Kim WS, Ryu KJ, Kim SJ, Park C. CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL Blood Cancer J. 2018 Feb 22;8(2):23.

Yi JH, Kim SJ, Kim WS. Brentuximab vedotin: clinical updates and practical guidance Blood Res. 2017 Dec;52(4):243-253

Yi JH, Kim SJ, Kim WS. Recent advances in understanding and managing T-cell lymphoma F1000Res. 2017 Dec 12;6:2123

Takayama T, Shin S, Kang S, Kim SJ, Kim WS, Ko YH. Identification of T-cell receptor expression in EBV-positive neoplastic cells in extranodal NK/T-cell lymphoma, nasal-type, and comparison with T-cell receptor gene rearrangement by BIOMED-2 assay. Hum Pathol. 2018 Mar;73:51-58.

Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol. 2018 Mar 1;29(3):707-714

Tang T, Khoo LP, Lim C, Ham JS, Kim SJ, Hong H, Phipps C, Lee YS, Tao M, Quek R, Farid M, Lin T, Kim WS, Lim ST. Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers Blood Cancer J. 2017 Dec 15;7(12):653

Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma N Engl J Med. 2018 Jan 25;378(4):331-344

Hong J, Kim SJ, Chang MH, Kim JA, Kwak JY, Kim JS, Yoon DH, Lee WS, Do YR, Kang HJ, Eom HS, Park Y, Won JH, Mun YC, Kim HJ, Kwon JH, Kong JH, Oh SY, Lee S, Bae SH, Yang DH, Jun HJ, Lee HS, Yun HJ, Lee SI, Kim MK, Yi JH, Lee JH, Kim WS, Suh C. Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma Oncotarget. 2017 Sep 18;8(54):92171-92182

Kang D, Cho J, Kim IR, Kim MK, Kim WS, Kim SJ. Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study. Cancer Res Treat. 2018 Oct;50(4):1051-1063

Ham JS, Park HY, Ryu KJ, Ko YH, Kim WS, Kim SJ. Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma Oncotarget. 2017 Jul 17;8(44):76231-76240.

Kwong YL, Kim SJ, Tse E, Oh SY, Kwak JY, Eom HS, Do YR, Mun YC, Lee SR, Shin HJ, Suh C, Chuang SS, Lee YS, Lim ST, Izutsu K, Suzuki R, Relander T, d'Amore F, Schmitz N, Jaccard A, Kim WS. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma Ann Oncol. 2018 Jan

Kim WS, Ogura M, Kwon HC, Choi D Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer. Future Oncol. 2017 May;13(15s):17-29

Seo J, Kim WS, Kim JS, Kim SJ, Lee JH, Hong JS, Lee GW, Oh SY, Lee JH, Yoon DH, Lee WS, Kim HJ, Kwak JY, Kang HJ, Jo JC, Park Y, Lee HS, Kim HJ, Suh C. Platelet to lymphocyte ratio (PLR) wskimsmc222retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. Blood Res. 2017 Sep;52(3):200-206

Kim HY, Jang MA, Kim HJ, Kim SJ, Kim WS, Kim SH. Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma. Blood Res. 2017 Sep;52(3):193-199. doi:

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2017 Dec 10;35(35):3898-3905

Park JS, Lim DH, Ahn YC, Park W, Kim SJ, Kim WS, Kim K. Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy Jpn J Clin Oncol. 2017 Nov 1;47(11):995-1001

Younes A, Salles G, Martinelli G, Bociek RG, Barrigon DC, Barca EG, Turgut M, Gerecitano J, Kong O, Pisal CB, Tavorath R, Kim WS. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 2017 ;102(12):2104-2112

Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017 Nov 1;35(31):3529-3537

Kim WS, Coiffier B, Kwon HC, Kim S Clinical development of CT-P10 and other biosimilar cancer therapeutics. Future Oncol. 2017 May;13(15s):31-44

Heo MH, Park HY, Ko YH, Kim WS, Kim SJ. IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. J Cancer. 2017 Mar 29;8(6):1018-1024. doi: 10.7150/jca.17358

Md GI, Oh D, Kim WS, Kim SJ, Ko YH, Woo KI, Kim YD, Ahn YC Low Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-cell Lymphoma. Cancer Res Treat. 2017 Jun 16. doi: 10.4143/crt.2017

Suh C, Park BB, Kim WS; CISL The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective. Blood Res. 2017 Mar;52(1):3-6. doi: 10.5045/br.2017

Kim HS, Ryu KJ, Ko YH, Kim HJ, Kim SH, Kim WS, Kim SJ Macrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma. Hematol Oncol. 2016 Feb 29 4.

Cho J, Kang D, Kim IR, Kim WS, Ferrell B, Kim SJ. Validation of the Korean Version of the Quality of Life-Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors. Cancer Res Treat. 2017 Mar 30. doi: 10.4143/crt.2017.091

Shin SY, Lee ST, Kim HJ, Oh YL, Kim SJ, Kim WS, Kim SH Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma. Ann Lab Med. 2016 May;36(3):209-14

Nanni C, Cottereau AS, Lopci E, Bodet-Milin C, Coronado M, Pro B, Kim WS, Trotman J, Barrington S, Duhrsen U, Vander Borght T, Zamagni E, Kraeber-Bodéré F, Messiou C, Rahmouni A, Buvat I, Andre M, Hertzberg M, Oyen W, Casasnovas O, Luminari S, Garderet L, Montravers F, Kobe C, Kluge R, Versari A, Zucca E, Moreau P, Cheson B, Haioun C, Gallamini A, Meignan M. Report of the 6th International Workshop on PET in lymphoma. Leuk Lymphoma. 2017 Oct;58(10):2298-2303. doi: 10.1080/10428194.2017

Jung H, Yoo HY, Lee SH, Shin S, Kim SC, Lee S, Joung JG, Nam JY, Ryu D, Yun JW, Choi JK, Ghosh A, Kim KK, Kim SJ, Kim WS, Park WY, Ko YH. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP. Oncotarget. 2017 Mar 7;8(10):17038-17049

Maeng CH, Ahn SW, Ryu SY, Han S, Ko YH, Ji JH, Kim WS, Kim SJ Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy. Korean J Intern Med. 2016 Feb 22

Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJS, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica. 2017 May;102(5):903-909.

Hong JY, Ryu KJ, Park C, Hong M, Ko YH, Kim WS, Kim SJ. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Oncotarget. 2017 Feb 21;8(8):13782-13791

Kim JH, Kim WS, Hong JY, Ryu KJ, Kim SJ, Park C. Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-κB and Btk. Oncotarget. 2017 Jan 17;8(3):5361-5370.

Hong JY, Ryu KJ, Lee JY, Park C, Ko YH, Kim WS, Kim SJ. Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma. Hematol Oncol. 2016 Dec 12. doi: 10.1002/hon.2374

Ryu KJ, Park C, Hong M, Ko YH, Kim WS, Kim SJ. FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma. Oncotarget. 2017 Jan 10;8(2):2466-2476

Park HY, Lee SB, Yoo HY, Kim SJ, Kim WS, Kim JI, Ko YH. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma. Oncotarget. 2016 Dec 27;7(52):86433-86445

Jung KS, Cho SH, Kim SJ, Ko YH, Kim WS. Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma. Int J Hematol. 2016 Nov;104(5):591-595

Seo S, Hong JY, Yoon S, Yoo C, Park JH, Lee JB, Park CS, Huh J, Lee Y, Kim KW, Ryu JS, Kim SJ, Kim WS, Yoon DH, Suh C. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Oncotarget. 2016 Nov 22;7(47):76934-76943

Shin SY, Lee ST, Kim HY, Park CH, Kim HJ, Kim JW, Kim SJ, Kim WS, Kim SH Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas. Blood Res. 2016 Sep;51(3):181-186

Moon SH, Lee AY, Kim WS, Kim SJ, Cho YS, Choe YS, Kim BT, Lee KH Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2017 Jun;58(6):1341-1348

Kim SJ, Hong JS, Chang MH, Kim JA, Kwak JY, Kim JS, Yoon DH, Lee WS, Do YR, Kang HJ, Eom HS, Park Y, Won JH, Mun YC, Kim HJ, Kwon JH, Kong JH, Oh SY, Lee S, Bae SH, Yang DH, Jun HJ, Kim YS, Yun HJ, Lee SI, Kim MK, Park EK, Kim WS, Suh C. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. Oncotarget. 2016 Nov 1;7(44):72033-72043. doi: 10.18632/oncotarget.12459

Son SM, Ha SY, Yoo HY, Oh D, Kim SJ, Kim WS, Ko YH. Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression. Mod Pathol. 2017 Jan;30(1):4-14. Doi

Song HN, Kim SJ, Ko YH, Kim WS. Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma. Acta Haematol. 2016;136(3):186-90

Hong JY, Suh C, Kim WS. Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update. F1000Res. 2016 Aug 8;5. pii: F1000 Faculty Rev-1933.

Yoon DH, Kim SJ, Jeong SH, Shin DY, Bae SH, Hong J, Park SK, Yhim HY, Yang DH, Lee H, Kang HJ, Lee MH, Eom HS, Kwak JY, Lee JH, Suh C, Kim WS. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Oncotarget. 2016 Dec 20;7(51):85584-85591

Bellei M, Sabattini E, Pesce EA, Ko YH, Kim WS, Cabrera ME, Martinez V, Dlouhy I, Paes RP, Barrese T, Vassallo J, Tarantino V, Vose J, Weisenburger D, Rüdiger T, Federico M, Pileri S. Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study. Hematol Oncol. 2016 Jun 3. doi: 10.1002/hon.2316

Maeng CH, Ko YH, Lim DH, Kang ES, Choi JY, Kim WS, Kim SJ Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma. Cancer Res Treat. 2017 Jan;49(1):92-103.

Jung KS, Cho SH, Kim SJ, Ko YH, Kang ES, Kim WS. L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia. J Hematol Oncol. 2016 Apr 18;9:41. doi: 10.1186/s13045-016-0271-4.

Shin DY, Kim SJ, Yoon DH, Park Y, Kong JH, Kim JA, Kim BS, Kim HJ, Won JH, Park SK, Kim WS. Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. Cancer Chemother Pharmacol. 2016 Apr;77(4):865-73

Kim HS, Ryu KJ, Ko YH, Kim HJ, Kim SH, Kim WS, Kim SJ. Macrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma. Hematol Oncol. 2016 Feb 29. doi: 10.1002/hon.2283

Shin SY, Lee ST, Kim HJ, Oh YL, Kim SJ, Kim WS, Kim SH. Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma. Ann Lab Med. 2016 May;36(3):209-14.

Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016 Feb 9.

Ham JS, Kim SJ, Choi JY, Hyun SH, Choi SK, Kim HS, Lim SH, Lee JY, Jung SH, Ko YH, Kim WS The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma. Blood Cancer J. 2016 Feb 12;6:e395

Kim SJ, Shin DY, Kim JS, Yoon DH, Lee WS, Lee H, Do YR, Kang HJ, Eom HS, Ko YH, Lee SH, Yoo HY, Hong M, Suh C, Kim WS A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Ann Oncol. 2016 Feb

Lim SH, Hyun SH, Kim HS, Lee JY, Yoo KH, Jung KS, Song HN, Cho J, Park S, Ko YH, Kim SJ, Choi JY, Kim WS Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL.Bone Marrow Transplant. 2016 Feb 8

Cho SH, Suh C, Do YR, Lee JJ, Yun HJ, Oh SY, Lee HS, Cho SG, Cho IS, Lee WS, Won YW, Kim HJ, Lee HG, Lee SI, Lim SN, Sohn BS, Ahn HJ, Chang MH, Kwon KA, Kim WS Clinical Features and Survival of Patients With Follicular Lymphoma in Korea. Clin Lymphoma Myeloma Leuk. 2016 Jan 6

Lee SE, Kang SY, Yoo HY, Kim SJ, Kim WS, Ko YH Clonal relationships in recurrent B-cell lymphomas. Oncotarget. 2016 Feb

Yoo HY, Kim P, Kim WS, Lee SH, Kim S, Kang SY, Jang HY, Lee JE, Kim J, Kim SJ, Ko YH, Lee S Frequent CTLA4-CD28 gene fusion in diverse types of T cell lymphoma. Haematologica. 2016 Jan 27

Kim HK, Moon SM, Moon JH, Park JE, Byeon S, Kim WS Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. Blood Res. 2015 Dec;50(4):254

Lee S, Kim MJ, Kim JS, Oh SY, Kim SJ, Kwon YH, Chung IY, Kang JH, Yang DH, Kang HJ, Yoon DH, Kim WS, Kim HJ, Suh C Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. Blood Res. 2015 Dec;50(4):242-7

Kim JS, Yoon DH, Park S, Yoon SS, Cho SG, Min CK, Lee JJ, Yang DH, Kwak JY, Eom HS, Kim WS, Kim H, Do YR, Moon JH, Lee J, Suh C Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. Ann Hematol. 2016 Jan 11

Kim SM, Park S, Oh DR, Ahn YC, Ko YH, Kim SJ, Kim WS Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability. Ann Hematol. 2016 Jan 4

Kim JH, Kim WS, Ryu K, Kim SJ, Park C CD79B limits response of diffuse large B cell lymphoma to ibrutinib. Leuk Lymphoma. 2015 Dec 24:1-10

Tan D, Phipps C, Hwang WY, Tan SY, Yeap CH, Chan YH, Tay K, Lim ST, Lee YS, Kumar SG, Ng SC, Fadilah S, Kim WS, Goh YT; SGH651 investigators Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol. 2015 Aug;2(8):e326-33

Kim SJ, Choi JY, Hyun SH, Ki CS, Oh D, Ahn YC, Ko YH, Choi S, Jung SH, Khong PL, Tang T, Yan X, Lim ST, Kwong YL, Kim WS; Asia Lymphoma Study Group. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematol. 2015 Feb;2(2):e66-74

Kim SJ, Kim JH, Ki CS, Ko YH, Kim JS, Kim WS Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. Ann Oncol. 2016 Mar;27(3):508-13

Kim HS, Lee HW, Kim WS, Ko YH Systemic Epstein-Barr virus-negative mature natural killer-cell lymphoma with cutaneous and visceral involvement. APMIS. 2015 Nov;123(11):990-

Lee MY, Kim HS, Lee JY, Lim SH, Kang ES, Ko YH, Kim SJ, Kim WS Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement. Int J Hematol. 2015 Oct 22

Oh D, Ahn YC, Kim SJ, Kim WS, Ko YH Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):677-83

Kim SJ, Ryu KJ, Hong M, Ko YH, Kim WS Erratum to: The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients. J Hematol Oncol. 2015 Oct 8;8(1):112.

Oh SY, Kim WS, Kim JS, Chae YS, Lee GW, Eom HS, Ryoo HM, Lee S, Kim SJ, Yoon DH, Won JH, Hong J, Park J, Lee SM, Hong JY, Park E, Kim HJ, Yang DH, Kim HJ, Suh C. A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial Leuk Lymphoma. 2015 Nov 16:1-7

Lee SH, Kim JS, Kim J, Kim SJ, Kim WS, Lee S, Ko YH, Yoo HY A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients. Haematologica. 2015 Dec;100(12):e505-7

Hong JY, Ko YH, Kim SJ, Kim WS Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a concise review and update. Curr Opin Oncol. 2015 Sep;27(5):392-8

Park BB, Kim WS, Suh C, Shin DY, Kim JA, Kim HG, Lee WS Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol. 2015 Nov;94(11):1845-51

Koh MS, Kim WS, Kim SJ, Oh SY, Yoon DH, Lee SI, Hong J, Song MK, Shin HJ, Kwon JH, Kim HJ, Do YR, Suh C, Kim HJ Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study. Int J Hematol. 2015 Oct;102(4):420-5.

Cho HJ, Jang MS, Hong SD, Kim SJ, Ahn YC, Oh D, Ko YH, Kim HY, Dhong HJ, Chung SK, Kim WS. Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type. Int Forum Allergy Rhinol. 2015 Oct;5(10):960-

Lim do H, Kim WS, Kim SJ, Yoo HY, Ko YH. Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma. Anticancer Res. 2015 Jun;35(6):3333-40

Lee S, Park HY, Kang SY, Kim SJ, Hwang J, Lee S, Kwak SH, Park KS, Yoo HY, Kim WS, Kim JI, Ko YH. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget. 2015 Jul 10;6(19):17764-76

.Kim SJ, Ryu KJ, Hong M, Ko YH, Kim WS. The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients J Hematol Oncol. 2015 May 14;8:49

Yhim HY, Kim JS, Mun YC, Moon JH, Chae YS, Park Y, Jo JC, Kim SJ, Yoon DH, Cheong JW, Kwak JY, Lee JJ, Kim WS, Suh C, Yang DH; Consortium for Improving Survival of Lymphoma Study. Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma Biol Blood Marrow Transplant. 2015 Sep;21(9):1597-604

Hong JY, Hong ME, Choi MK, Chang W, Do IG, Jo JS, Jung SH, Park S, Kim SJ, Ko YH, Kim WS The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma. Anticancer Res. 2015 Apr;35(4):2465-74

Yoon H, Park S, Ju H, Ha SY, Sohn I, Jo J, Do IG, Min S, Kim SJ, Kim WS, Yoo HY, Ko YH. Integrated copy number and gene expression profiling analysis of Epstein-Barr virus-positive diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2015 Jun;54(6):383-96

Lim SH, Woo SY, Kim S, Ko YH, Kim WS, Kim SJ. Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism. Cancer Res Treat. 2016 Jan;48(1):312-21

Park S, Kang CI, Chung DR, Peck KR, Kim WS, Kim SJ. Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis. Cancer Res Treat. 2015 Jul;47(3):448-57

Kim MJ, Hong ME, Maeng CH, Jung HA, Hong JY, Choi MK, Kim SJ, Ko YH, Kim WS. Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea. Int J Hematol. 2015 Mar;101(3):273-8

Kim SJ, Hong M, Do IG, Lee SH, Ryu KJ, Yoo HY, Hong JY, Ko YH, Kim WS. Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator. Haematologica. 2015 Mar;100(3):e106-9

Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, Jo J, Jung SH, Hong ME, Yoon H, Ko YH, Kim SJ, Kim WS. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol. 2015 Mar;26(3):548-55

Yang QM, Hong JY, Ko YH, Lin SY, Au WY, Choi MK, Park S, Kim SJ, Kim WS. Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia. Onco Targets Ther. 2014 Sep 26;7:1717-22

Jung SH, Lee JJ, Kim WS, Lee WS, Do YR, Oh SY, Kim MK, Mun YC, Shin HJ, Kwak JY, Kang HJ, Won JH, Kwon JH, Park E, Suh C, Yang DH. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). Eur J Haematol. 2015 Jun;94(6):504-10.

Min KW, Jung HY, Han HS, Hwang TS, Kim SY, Kim WS, Lim SD, Kim WY. Ileal mass-like lesion induced by Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a patient with aplastic anemia. APMIS. 2015 Jan;123(1):81-6

Kim SJ, Park S, Kang ES, Choi JY, Lim do H, Ko YH, Kim WS. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. Ann Hematol. 2015 Jan;94(1):71-8. doi: 10.1007/s00277-014-2171-4

Lee GW, Go SI, Kim SH, Hong J, Kim YR, Oh S, Kim SY, Do YR, Lee H, Lee SI, Bae SH, Oh SY, Song MK, Lee WS, Lee B, Kim JS, Kim MK, Kang HJ, Ahn JS, Yhim HY, Kim HJ, Kim SJ, Kim WS, Suh C; Consortium for Improving Survival of Lymphoma (CISL) study group. Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. Leuk Lymphoma. 2015 Apr;56(4):1020-

Kim SJ, Choi JY, Hyun SH, Ki CS, Oh D, Ahn YC, Ko YH, Choi S, Hung SH, Khong PL, Tang T, Yan X, Lim ST, Kwong YL, Kim WS Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis Lancet Hematol 2015

Lim SH, Woo SY, Kim S, Ko YH, Kim WS, Kim SJ Cross-sectional Study of Patients with Diffuse Large B-cell lymphoma: Assessing the Effect of Host Status, Tumor Burden and Inflammatory Activity on Venous Thromboembolism. Cancer Res Treat. 2015 Mar 2

Kim SM, Lee ST, Ryu KJ, Kim HJ, Kim SH, Ko YH, Kim WS, Kim SJ A subset of CD45+/CD19+ cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma. Leuk Lymphoma. 2015 Mar 5:1-12

Lee KH, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience. .Vox Sang. 2014 Nov;107(4):407-15

Park S, Kang CI, Chung DR, Peck KR, Kim WS, Kim SJ Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis. Cancer Res Treat. 2014 Nov 3

Tateishi U, Tatsumi M, Terauchi T, Ando K, Niitsu N, Kim WS, Suh C, Ogura M, Tobinai K Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 2015 Feb;106(2):

Kim MJ, Hong ME, Maeng CH, Jung HA, Hong JY, Choi MK, Kim SJ, Ko YH, Kim WS Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea. ***Int J Hematol***. 2015 Jan 1.

T Hong J, Kim SJ, Ahn J, Song MK, Kim YR, Lee HS, Yhim H, Yoon DH, Kim MK, Oh SY, Park Y, Mun Y, Do YR, Ryoo H, Lee J, Lee JH, Kim WS, Suh C reatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. ***Cancer Res Treat***. 2014

Tateishi U, Tatsumi M, Terauchi T, Ando K, Niitsu N, Kim WS, Suh C, Ogura M, Tobinai K Prognostic Significance of Metabolic Tumor Burden by PET/CT in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma. ***Cancer Sci.*** 2014 Dec 13

Kim SJ, Hong M, Do IG, Lee SH, Ryu KJ, Yoo HY, Hong JY, Ko YH, Kim WS Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator. ***Haematologic***a. 2014

Hong JY, Yoon DH, Suh C, Huh J, Do I, Sohn I, Jo J, Jung S, Hong ME, Yoon H, Ko YH, Kim SJ, Kim WS EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? ***Ann Oncol***. 2014

Yoo KH, Lee JY, Lim SH, Ko YH, Kim SJ, Kim WS Pilot Trial of Systemic Methotrexate plus R-CHOP Regimen with Intrathecal Methotrexate for Simultaneous Central Nervous System and Systemic Diffuse Large B Cell Lymphoma. ***Acta Haematol***. 2014 Oct 11;133(2):179-182

Jung SH, Lee JJ, Kim WS, Lee WS, Do YR, Oh SY, Kim MK, Mun YC, Shin HJ, Kwak JY, Kang HJ, Won JH, Kwon JH, Park E, Suh C, Yang DH Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). ***Eur J Haematol***. 2014

Lee KH, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience. ***Vox Sang***. 2014 Nov;107(4):407-15

Kim SJ, Park S, Kang ES, Choi JY, Lim do H, Ko YH, Kim WS Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. ***Ann Hematol***. 2015 Jan;94(1):71-8

Lee GW, Go SI, Kim SH, Hong J, Kim YR, Oh S, Kim SY, Do YR, Lee H, Lee SI, Bae SH, Oh SY, Song MK, Lee WS, Lee B, Kim JS, Kim MK, Kang HJ, Ahn JS, Yhim HY, Kim HJ, Kim SJ, Kim WS, Suh C; for the Consortium for Improving Survival of Lymphoma (CISL) study group Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. ***Leuk Lymphoma***. 2014 Aug 20:1-7

Ha JM, Kim E, Lee WJ, Hwang JW, Yune S, Ko YH, Choi JY, Kim SJ, Kim WS. Unusual manifestation of intravascular large B-cell lymphoma: severe hypercalcemia with parathyroid hormone-related protein. ***Cancer Res Treat***. 2014 Jul;46(3):307-11

Kim SJ, Yang DH, Kim JS, Kwak JY, Eom HS, Hong DS, Won JH, Lee JH, Yoon DH, Cho J, Nam TK, Lee SW, Ahn YC, Suh C, Kim WS Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. **Ann Hematol. 2014 Jun 20**

Kim SH, Kim IR, Kim SH, Lee S, Ok O, Kim WS, Suh C, Lee MH Health-related quality of life in Korean lymphoma survivors compared with the general population. **Ann Hematol. 2014 Jun 20**

Lee SJ, Suh CW, Lee SI, Kim WS, Lee WS, Kim HJ, Choi CW, Kim JS, Shin HJ Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of

Waldeyer's ring: nationwide Korean study. ; Consortium for Improving Survival of Lymphoma. **Korean J Intern Med. 2014 May;29(3):352-60**

Hong JY, Kim HJ, Ko YH, Choi JY, Jung CW, Kim SJ, Kim WS Clinical features and treatment outcomes of intravascular large B-cell lymphoma: a single-center experience in Korea. **Acta Haematol. 2014;131(1):18-27**

Tse E, Chan TS, Koh LP, Chng WJ, Kim WS, Tang T, Lim ST, Lie AK, Kwong YL Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group. **Bone Marrow Transplant. 2014 Jul;49(7):902-6**

Kang BW, Sohn SK, Moon JH, Chae YS, Kim JG, Lee SJ, Kim WS, Lee JJ, Lee SR, Park KU, Lee HS, Lee WS, Won JH, Park MR, Kwak JY, Kim MK, Kim HJ, Oh SY, Kang HJ, Suh C Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. **Blood Res. 2014 Mar;49(1):15-21**

Kim JH, Kim WS, Park C PKD1 is critical for Epstein-Barr virus LMP1-induced protection of malignant B cells from cell death induced by rituximab.**Leuk Lymphoma. 2014 Jun 25:1-8**

Ogura M, Ando K, Suzuki T, Ishizawa K, Oh SY, Itoh K, Yamamoto K, Au WY, Tien HF, Matsuno Y, Terauchi T, Yamamoto K, Mori M, Tanaka Y, Shimamoto T, Tobinai K, Kim WS A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. **Br J Haematol. 2014 Jun;165(6):768-776**

Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, Kim SC, Lee B, Rho K, Lee JE, Cho KH, Kim W, Ju H, Kim J, Kim SJ, Kim WS, Lee S, Ko YH A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. ***Nat Genet. 2014 Apr;46(4):371-5***

Kim SJ, Kang HJ, Kim JS, Eom HS, Huh J, Ko YH, Lee J, Yim DS, Lee SY, Park WS, Yang WI, Lee SS, Suh C, Kim WS A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas **Invest New Drugs. 2013 Dec;31(6):1514-21**

Kim SJ, Sohn I, Do IG, Jung SH, Ko YH, Yoo HY, Paik S, Kim WS Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay. ***Ann Hematol*** 2014; 93: 437-447.

Chang WJ, Ko YH, Kim SJ, Kim WS. Dexamethasone, methotrexate, ifosfamide, l-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma. ***Leuk Lymphoma*** 2014.

Kim SJ, Sohn I, Do IG, Jung SH, Ko YH, Yoo HY, Paik S, Kim WS. Clinical features and treatment outcomes of intravascular large B-cell lymphoma: a single-center experience in Korea. ***Acta Haematol*** 2014; 131: 18-27

Park S, Han B, Cho JW et al. Effect of Nutritional Status on Survival Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP. ***Nutr Cancer*** 2014; 66: 225-233

Hong JY, Hong ME, Choi MK et al. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases***. Ann Oncol*** 2014; 25: 182-188

Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim WS, Ko YH . CD79B and MYD88 mutations in diffuse large B-cell lymphoma. ***Hum Pathol*** 2014; 45: 556-564

Choi MK, Kang ES, Kim DW, Ko YH, Seok H, Park JH, Pyo DH, Hoon Lim D, Kim SJ, Kim WS Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell **lymphoma**: a single-center experience of autologous stem cell transplantation. ***Int J Hematol. 2013 Sep;98(3):346-54***

Ohmachi K, Niitsu N, Uchida T et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma***. J Clin Oncol*** 2013; 31: 2103-2109

Suh C, Kim WS, Kim JS, Park BB. Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party. ***Blood Res*** 2013; 48: 171-177

an D, Tan SY, Lim ST et al. Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. ***Lancet Oncol*** 2013; 14: e548-561

Yi HG, Kim JS, Suh C et al. Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry. ***Blood Res*** 2013; 48: 115-120

Kim SJ, Jung HA, Chuang SS et al. Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma Study Group**.** ***J Hematol Oncol 2013; 6: 86***

Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group**.** ***Eur J Cancer. 2013 2013; 49: 3486-3496.***

MK, Kang ES, Kim DW, Ko YH, Seok H, Park JH, Pyo DH, Hoon Lim D, Kim SJ, Kim WS. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation. ***Int J Hematol. 2013 Jul 19***. [Epub ahead of print]

Yi HG, Kim JS, Suh C, Kim WS, Kwak JY, Lee JS, Kim YS, Joo YD, Min YH, Lee HG, Yoon SS, Won JH, Park S, Kim HC, Kim CS Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry. ***Blood Res. 2013 Jun;48(2):115-20***

Ha SY, Sung J, Ju H, Karube K, Kim SJ, Kim WS, Seto M, Ko YH Epstein-Barr virus-positive nodal peripheral T cell lymphomas: Clinicopathologic and gene expression profiling study. ***Pathol Res Pract. 2013 Jul;209(7):448-54***

Hong M, Ko YH, Yoo KH, Koo HH, Kim SJ, Kim WS, Park H. EBV-Positive T/NK-Cell Lymphoproliferative Disease of Childhood. ***Korean J Pathol. 2013 Apr;47(2):137-47***

Moon SH, Cho SK, Kim WS, Kim SJ, Chan Ahn Y, Choe YS, Lee KH, Kim BT, Choi JY The Role of 18F-FDG PET/CT for Initial Staging of Nasal Type Natural Killer/T-Cell Lymphoma: A Comparison with Conventional Staging Methods. ***J Nucl Med. 2013 Jul;54(7):1039-44***

Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, Terauchi T, Tateishi U, Tatsumi M, Kim WS, Tobinai K, Suh C, Ogura M Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma**.** ***J Clin Oncol. 2013 Jun 10;31(17):2103-9***

Lim SH, Lee JY, Lee JY, Kim JH, Choi KH, Hyun JY, Ko YH, Lee J, Kim SJ, Kim WS Unusual presentation of Ewing sarcoma in the adrenal gland: a secondary malignancy from a survivor of Burkitt lymphoma. ***Jpn J Clin Oncol. 2013 Jun;43(6):676-80***

Kang HJ, Lee SS, Byun BH, Kim KM, Lim I, Choi CW, Suh C, **Kim WS**, Nam SH, Lee SI, Eom HS, Shin DY, Lim SM Repeated radioimmunotherapy with (131)I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. ***Cancer Chemother Pharmacol.* 2013 Apr;71(4):945-53.**

Kim JH**, Kim WS**, Park C. Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma. ***Leuk Lymphoma. 2013*** Feb 28

Lee GY, **Kim WS**, Ko YH, Choi JO, Jeon ES. Primary cardiac lymphoma mimicking infiltrative cardiomyopathy. ***Eur J Heart Fail. 2012***

Ahn HK, Kim SJ, Hwang DW, Ko YH, Tang T, Lim ST, **Kim WS** Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. ***Invest New Drugs. 2013 Apr;31(2):469-72***

Kim SJ, Park Y, Kim BS, Kim I, Ko YH, **Kim WS** .Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype***?Korean J Hematol. 2012 Sep;47(3):202-6***

Oh SY**, Kim WS**, Kim JS, Kim SJ, Lee S, Lee DH, Lee SI, Kang HJ, Choi CW, Park J, Song MK, Kim HJ, Kwon JH, Kwak JY, Bae SH, Park BB, Do YR, Lee HS, Jeong SH, Suh C, Kim HJ. Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). ***Int J Hematol. 2012 Nov;96(5):631-7***

Lee MR, Ju HJ, Kim BS, Ko YH, **Kim WS**, Kim SJ Isolation of side population cells in B-cell non-Hodgkin's lymphomas. ***Acta Haematol. 2013;129(1):10-7***

Jang SJ, Lee KH, Lee JY, Choi JY, Kim BT, Kim SJ, **Kim WS** (11)C-methionine PET/CT and MRI of primary central nervous system diffuse large B-cell lymphoma before and after high-dose methotrexate. ***Clin Nucl Med. 2012 Oct;37(10):e241-***

Kwong YL, **Kim WS**, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group**.** ***Blood. 2012 Oct 11;120(15):2973-80***

Kim YR, Kim JS, Min YH, Hyunyoon D, Shin HJ, Mun YC, Park Y, Do YR, Jeong SH, Park JS, Oh SY, Lee S, Park EK, Jang JS, Lee WS, Lee HW, Eom H, Ahn JS, Jeong JH, Baek SK, Kim SJ, **Kim WS**, Suh C. Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). ***J Hematol Oncol. 2012 Aug***

Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, **Kim WS**; On behalf of Consortium for Improving Survival of Lymphoma (CISL) investigators. *Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial* **Eur J Cancer. 2012 Jul 4**

Jung HA, Park S, Cho JH, Kim S, Ko YH, Kim SJ**, Kim WS**. *Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study* **Ann Hematol. 2012 Jun 28**

Park S, Moon SH, Park LC, Hwang DW, Ji JH, Maeng CH, Cho SH, Ahn HK, Lee JY, Kim SJ, Choi JY, **Kim WS.** *The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma***Am J Hematol. 2012 May**

Yeom SY, Lee SJ, **Kim WS**, Park C. *Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells.* **Leuk Res. 2012 Sep;36(9):1172-8.**

Tse E, Gill H, Loong F, Kim SJ, Ng SB, Tang T, Ko YH, Chng WJ, Lim ST, **Kim WS**, Kwong YL. *Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group***.** **Am J Hematol. 2012 Jul;87(7):663-**

Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, Huh JR, Yoon DH, Oh SY, Kim JS, Lee SI, Park KW, Hsieh PP, Nakamura S, Yoshino T, Ito K, Nagatani T, Oshimi K, Suzuki R, **Kim WS**. *Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from mltinational retrospective analysis* **Ann Oncol. 2012 Apr 29**

Park LC, Woo SY, Kim S, Jeon H, Ko YH, Kim SJ, Kim WS .*Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients*: **Thromb Res. 2012 Apr 14**

Kim JE, Yoon DH, Jang G, Lee DH, Kim S, Park CS, Huh J, **Kim WS**, Park J, Lee JH, Lee SI, Suh C. *Results from a prospective cohort study with Asian populationA phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas*. **Korean J Hematol. 2012 Mar;47(1):53-9**

Kim SJ, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, Issaragrisil S, Kwak JY, Lee JJ, Won JH, Reksodiputro AH, Lim ST, Cheng AL**, Kim WS**, Kwong YL *Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group*. **Leuk Lymphoma. 2012 Mar 1**

Kim JH, **Kim WS**, Park *C Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1*. **Leuk Lymphoma. 2012 Mar 1**

Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, **Kim WS**, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM; International Peripheral T-cell Lymphoma Project. *Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project* ***Blood***. 2011 Mar 24;117(12):3402-8.

Lim T, Kim SJ, Kim K, Lee JI, Lim do H, Lee DJ, Baek KK, Lee HY, Han B, Uhm JE, Ko YH, Kim WS. *Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes* ***Ann Hematol***. 2011 Dec;90(12):1391-8.

Yamaguchi M, Kwong YL, **Kim WS**, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R. *Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study* ***J Clin Oncol****. 2011 Oct 11. [Epub ahead of print]*

Yang DH, **Kim WS**, Kim SJ, Kim JS, Kwak JY, Chung JS, Oh SY, Suh CW, Lee JJ. *Pilot trial of yttrium-90 ((90)Y)-ibritumomab tiuxetan consolidation following R-CHOP chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma* ***Leuk Lymphoma****. 2011 Oct 31*

Kim K, Kim MJ, Ahn S, Bae SY, **Kim WS**, Yoon JH. *Frontal sinus lymphoma presenting as progressive multiple cranial nerve palsy* ***Yonsei Med J***. 2011 Nov 1;52(6):1044-7

Na YJ, Kim ER, Kim SJ, **Kim WS**, Ko YH, Son HJ. *Primary Gastrointestinal Follicular Lymphoma: Single-Center 12 Year Experiences* ***Hepatogastroenterology.*** *2011 Sep 29;59(115-116).*

Choi SY, Kim SJ, **Kim WS**, Kim K, Ko YH. *Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis* ***Virchows Arch***. 2011 Nov;459(5):495-502

Kang HJ, **Kim WS**, Kim SJ, Lee JJ, Yang DH, Kim JS, Lee SR, Lee GW, Kim HJ, Kim HY, Oh SY, Kim HC, Eom HS, Chung J, Park J, Suh C, Ryoo BY. *Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study* ***Ann Hematol***. 2011 Sep 16

Yhim HY, Kim JS, Kang HJ, Kim SJ, **Kim WS**, Choi CW, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Huh J, Lee DH, Suh C, Kwak JY. *Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy* ***Int J Cancer***. 2011 Aug 5.

Lee HY, Kim SJ, Kim K, Ko YH, ***Kim WS****. Bone involvement in patients with stage IV diffuse large B-cell lymphoma: does it have a prognostic value?* ***Leuk Lymphoma. 2011 Sep 23***

Kim SJ, Choi CW, Mun YC, Oh SY, Kang HJ, Lee SI, Won JH, Kim MK, Kwon JH, Kim JS, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Lee JH, Oh S, Park KW, Suh C, ***Kim WS****. Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL).* ***BMC Cancer****. 2011 Jul 29;11:321*

Won YW, Kwon JH, Lee SI, Oh SY, **Kim WS**, Kim SJ, Won JH, Kim KH, Park SK, Kim JS, Suh C, Yoon H, Park JS, Kim MK, Kim H, Kang HJ, Mun YC, Kwak JY, Kim HJ, Eom HS *Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL).* ***Ann Hematol****.* 2011 Jul 26.

Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, **Kim WS** *Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone..* ***Blood.*** 2011 Feb 10;117(6):1958-65

Yi JH, Kim JH, Baek KK, Lim T, Lee DJ, Ahn YC, Kim K, Kim SJ, Ko YH, **Kim WS**. *Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma.* ***Ann Oncol***. 2011 Jul;22(7):1636-43

Sung CO, Kim SC, Karnan S, Karube K, Shin HJ, Nam DH, Suh YL, Kim SH, Kim JY, Kim SJ, **Kim WS**, Seto M, Ko YH *Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma.* **Blood.** 2011 Jan 27;117(4):1291-300

Kim SJ, **Kim WS**. *Treatment of localized extranodal NK/T cell lymphoma, nasal type. Review* **Int J Hematol.** 2010 Dec;92(5):690-6.

Yi JH, Kim SJ, Ko YH, **Kim WS** *Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy.* **Leuk Lymphoma.** 2010 Nov 11

Kim SJ, Oh SY, Kim JS, Kim H, Lee GW, Won JH, Shin HJ, Yang DH, Choi CW, Park J, **Kim WS**, Suh C. *Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.* **Ann Hematol.** 2010 Oct 20.

Lee SC, Kim SJ, Lee DH, **Kim WS**, Suh C, Won JH *Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma.* **Bone Marrow Transplant.** 2010 Apr;45(4):801-2.

Oh SY, **Kim WS**, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Lee WS, Suh C, Kim HJ *Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study.* **Int J Hematol**. 2010 Sep 14.

Kang BW, **Kim WS**, Kim C, Jang G, Lee SS, Choi YH, Lee DH, Kim SW, Kim S, Ryu JS, Huh J, Lee JS, Suh C *Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.* **Invest New Drugs**. 2010 Aug;28(4):516-22.

Kim JH, **Kim WS**, Yun Y, Park C *Epstein-Barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1.* **Cell Signal**. 2010 Dec;22(12):1858-63.

Kim SJ, Kim K, Park Y, Kim BS, Huh J, Ko YH, Park K, Suh C, **Kim WS** *Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity.* **Invest New Drugs**. 2010 Aug 24

Oh SY, **Kim WS**, Kim JS, Kim SJ, Kwon HC, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Lee GW, Choi CW, Park J, Suh C, Kim HJ *Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or*

chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study. **Ann Hematol**. 2010 Jun;89(6):563-8.

Yhim HY, Kang HJ, Choi YH, Kim SJ, **Kim WS**, Chae YS, Kim JS, Choi CW, Oh SY, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Lee JJ, Sung HJ, Kim HJ, Lee DH, Suh C, Kwak JY *Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.* **BMC Cancer**. 2010 Jun 22;10:321

Won YW, Kim SJ, Kim K, Ko YH, **Kim WS**. *Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea.* **Ann Hematol**. 2010 Oct;89(10):1011-8.

Ko YH, Karnan S, Kim KM, Park CK, Kang ES, Kim YH, Kang WK, Kim SJ, **Kim WS**, Lee WY, Chun HK, Seto M *Enteropathy-associated T-cell lymphoma--a clinicopathologic and array comparative genomic hybridization study.* **Hum Pathol**. 2010 Sep;41(9):1231-7.

Ahn HK, Kim SJ, Yun J, Yi JH, Kim JH, Won YW, Kim K, Ko YH, **Kim WS** *Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients.* .**Int J Hematol**. 2010 Apr; 91(3):456-63.

Yu JI, Nam H, Ahn YC, **Kim WS**, Park K, Kim SJ *Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma.* **Int J Radiat Oncol Biol Phys.** 2010 Oct 1;78(2):507-12.

Yun J, Kim SJ, Kim JA, Kong JH, Lee SH, Kim K, Ko YH, **Kim WS** *Clinical features and treatment outcomes of non-Hodgkin's lymphomas involving rare extranodal sites: a single-center experience.* **Acta Haematol**. 2010;123(1):48-54.

Kim SJ, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, Ko YH, Ahn YC, Kim HJ, Suh C, Kim K, **Kim WS**. *When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?* **Ann Oncol**.. 2010 May;21(5):1058-63

Park S, Bahng S, Kim KE, Park BS, Sung KY, Kim SJ, **Kim WS** , Ko YH. *Hodgkin's Lymphoma Arising in a Patient With Hypersensitivity to Mosquito Bites: A Case Report* **J Clin Oncol**. 2010 Jan 11

Kwong YL, Anderson BO, Advani R, **Kim WS**, Levine AM, Lim ST *Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009* **Lancet Oncol** *1093-1101* Volume 10, Issue 11,

Oh SY, **Kim WS**, Kim SJ, Kim JS, Kim SH, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Kim JG, Yang DH, Kang HJ, Choi CW, Park J, Choi YJ, Kim HJ, Kwon JH, Suh C, Kim HJ. *Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases* **Am J Hematol**. 2009 Oct 8.

Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, **Kim WS**. *Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell*

Lymphoma: Consortium for Improving Survival of Lymphoma Study. **J Clin Oncol**. 2009 27(35)6027-6032

Lee SC, Kim SJ, Lee DH, **Kim WS**, Suh C, Won JH. *Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma*. **Bone Marrow Transplant**. 2009 Sep 21.

Park BB, **Kim WS**, Eom HS, Kim JS, Lee YY, Oh SJ, Lee DH, Suh C. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. **Invest New Drugs.** 2009 Sep 16.

Chang MH, Kim SJ, Kim K, Oh SY, Lee DH, Huh J, Ko YH, Choi CW, Yang DH, Won JH, **Kim WS**, Suh C. *Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea*. **Leuk Lymphoma.** 2009 Jul;50(7):1119-25.

Kang BW, **Kim WS**, Kim C, Jang G, Lee SS, Choi YH, Lee DH, Kim SW, Kim S, Ryu JS, Huh J, Lee JS, Suh C. *Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.* **Invest New Drugs**. 2009 Jun 23

Uhm JE, Kim KH, Yi SY, Chang MH, Park KW, Kong DS, Lee JI, Nam do H, Park W, Lim do H, Kim SJ, Kim K, Ko YH, **Kim WS** *A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma* **Leuk Lymphoma.** 2009 Jul;50(7):1110-8.

Yi JH, Kim SJ, Choi JY, Ko YH, Kim BT, **Kim WS**. (18)F-FDG uptake and its clinical relevance in primary gastric lymphoma. **Hematol Oncol**. 2009 Jul 10.

Choi MK, Jun HJ, Lee SY, Kim KH, Lim DH, Kim K, Ko YH, **Kim WS**, Kim SJ. Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. **Ann Hematol**. 2009 Mar 14

Kim HS, Kim KH, Kim KH, Chang MH, Ji SH, Lim do H, Kim K, Kim SJ, Ko Y, Ki CS, Jo SJ, Lee JW, **Kim WS.** Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. **Leuk Lymphoma**. 2009 May;50(5):757-63

Oh SY, **Kim WS**, Lee DH, Kim SJ, Kim SH, Ryoo BY, Kang HJ, Choi YJ, Chung JS, Kim HJ, Suh C Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. ***.Invest New Drugs****. 2009 May 7*

Hwang YC, Kim TY, Kim WB, Shong YK, Yi KH, Shong M, Jo YS, **Kim WS**, Chung JH. Clinical Characteristics of Primary Thyroid Lymphoma in Koreans **Endocr J**. 2009 Feb 18.

Yang DH, **Kim WS**, Kim SJ, Bae SH, Kim SH, Kim IH, Yoon SS, Mun YC, Shin HJ, Chae YS, Kwak JY, Kim H, Kim MK, Kim JS, Won JH, Lee JJ, Suh CW Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell

lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. **Biol Blood Marrow Transplant**. 2009 Jan;15(1):118-25

Kim MS, Lee JI, **Kim WS**, Ko YH. Primary central nervous system lymphoma after liver transplantation treated by radiosurgery combined with fractionated radiotherapy **J Clin Neurosci**. 2009 Feb 4. [Epub ahead of print]

Kim SJ, Kim K, Kim BS, Suh C, Huh J, Ko YH, **Kim WS**. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study **Ann Oncol**. 2009 Feb;20(2):390-2.

Choi KA, Lee JE, Kim YG, Kim DJ, Kim K, Ko YH, Oh HY, **Kim WS**, Huh W Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome ***Ann Hematol***. *2008 Nov 22*. Ko YH, Park S, Kim K, Kim SJ, **Kim WS**. Aggressive Natural Killer Cell Leukemia: Is Epstein-Barr Virus Negativity an Indicator of a Favorable Prognosis? **Acta Haematol**. 2009 Jan 20;120(4):199-206.

Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, **Kim WS**, Sng I, Vose J, Armitage JO, Liang R Clinical differences between nasal and extranasal NK/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell Lymphoma Project. ***Blood***. *2008 Nov 24.*

Nam H, Ahn YC, Kim YD, Ko Y, **Kim WS** Prognostic significance of anatomic subsites: Results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma ***Radiother Oncol***. *2008 Oct 22. [Epub ahead of print*]

Sym SJ, Lee DH, Kang HJ, Nam SH, Kim HY, Kim SJ, Eom HS, **Kim WS**, Suh C. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma ***Cancer Chemother Pharmacol***. *2008 Oct 7.*

Lee J, Suh C, Kang HJ, Ryoo BY, Huh J, Ko YH, Eom HS, Kim K, Park K, **Kim WS** Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma ***Ann Oncol***. *2008 Dec;19(12):2079-83*.

Lee Y, Uhm JE, Lee HY, Park MJ, Kim H, Oh SJ, Jang JH, Kim K, Jung CW, Ahn YC, Park K, Ko YH, **Kim WS** Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified" ***Ann Hematol***. *2008 Jul 22*

Park S, Kim K, **Kim WS**, Yoo KH, Koo HH, Ko YH Systemic EBV+ T-cell lymphoma in elderly patients: comparison with children and young adult patients. ***Virchows Arch*** *2008 Aug;453(2):155-63*

Kim JH, **Kim WS**, Park C SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death ***leuk Lymphoma*** *2008 49(7) :1392-8*

Honma K, Tsuzuki S, Nakagawa M, Karnan S, Aizawa Y, **Kim WS**, Kim YD, Ko YH, Seto M. TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. ***Genes Chromosomes Cancer.*** *2008 Jan;47(1):1-7.*

Yamaguchi M, Suzuki R, Kwong YL, **Kim WS**, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. ***Cancer Sci.*** *2008 Feb 19;*

Park BB, Kim JS, Lee YY, Kang HJ, Ryoo BY, Kang JH, Kim HY, Kim BS, Oh SY, Kwon HC, Won JH, Kim K, Park K, Suh C, **Kim WS** Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. **Leuk Lymphoma**. 2008 Jan;49(1):88-94.

Oh SY, Kwon HC, **Kim WS**, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo BY, Lee SS, Kim HY, Park K, Kim HJ Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. **Cancer Lett**. 2007 Dec 8;258(1):90-7.

Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, **Kim WS**, Kim DH, Suh C, Kim SJ, Eom HS, Bae SH. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. **Bone Marrow Transplant**. 2007 Nov;40(10):919-24

Lee J, Suh C, Huh J, Jun HJ, Kim K, Jung C, Park K, Park YH, Ko YH, **Kim WS** Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. ***Clin Cancer Res****. 2007 Jun 1;13(11):3250-4*

Hwang IG, Yoo KH, Lee SH, Park YH, Lim TK, Lee SC, Park S, Park BB, Ko YH, Kim K, Koo HH, **Kim WS** Clinicopathologic features and treatment outcomes in malignant lymphoma of pediatric and young adult patients in Korea: comparison of korean all-ages group and Western younger age group. **Clin Lymphoma Myeloma. 2007 Nov;7(9):580**

Kim WS, Honma K, Karnan S, Tagawa H, Kim YD, Oh YL, Seto M, Ko YH. Genome-wide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: comparison with pulmonary and nodal marginal zone B cell lymphoma.

Genes Chromosomes Cancer*. 2007 Aug;46(8):776-83.*

Kim JH, Lee JH, Lee J, Oh SO, Chang DK, Rhee PL, Kim JJ, Rhee JC, Lee J, **Kim WS**, Ko YH **Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings** ***Endoscopy*** *2007 Feb;39(2):156-60*

Park BB, Ryoo BY, Lee JH, Kwon HC, Yang SH, Kang HJ, Kim HJ, Oh SY, Ko YH, Huh JR, Lee SS, Nam EM, Park KW, Kim JH, Kang JH, Bang SM, Park S, Kim K, Park K, Suh C, **Kim WS**. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. ***Leuk Lymphoma****. 2007 Apr;48(4):716-22*

Park BB, Kim JG, Sohn SK, Kang HJ, Lee SS, Eom HS, Kwon HC, Oh SY, Kang JH, Oh SJ, Shin HJ, Suh C, Kim JH, Kim HY, Kim K, Ryoo BY, **Kim WS**. Consideration of aggressive therapeutic strategies for primary testicular lymphoma. ***Am J Hematol****. 2007 Jun 11; [Epub ahead of print*

Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, Hwang IG, Park YH, Ahn JS, Jung CW, Kim K, Ahn YC, Kang WK, Park K, **Kim WS** The impact of the Epstein-Barr Virus status on clinical outcome in diffuse large B cell lymphoma. ***Blood.*** *2007 Aug 1;110(3):972-8*

Han A, Lee HR, Park BB, Hwang IG, Park S, Lee SC, Kim K, Lim HY, Ko YH, Kim SH, **Kim WS** Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. ***Ann Hematol****. 2007 Jul;86(7):493-8*

Oh SY, Ryoo BY, **Kim WS**, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kim HJ, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases. ***Am J Hematol****. 2007 Jan 31;*

Kim JH, **Kim WS**, Kang JH, Im HY, Park C Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1. ***FEBS Lett****. 2007 Feb 20;581(4):623-8*

Kim HJ, Bang SM, Lee J, Kwon HC, Suh C, Kim HJ, Lee JH, Ryoo BY, Park YH, Kwon JM, Oh SY, Lee HR, Kim K, Jung CW, Park K, **Kim WS** **High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases.** *Bone Marrow Transplant. 2006 May;37(9):819-24*

Cho JH, Park YH, **Kim WS**, Oh SY, Cho SI, Kang HJ, Na II, Ryoo BY, Yang SH, Kim K, Jung CW, Park K, Ko YH, Lee SS. **High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: a clinicopathologic study of 18 casesin the Korean population**. *Leuk Lymphoma. 2006 Oct;47(10):2128-31.*

Park YH, **Kim WS**, Bang SM, Lee SI, Uhm JE, Yang SH, Lee SS, Park K, Ko YH, Ryoo BY. **What is stage II in high-grade primary gastric lymphoma? How to define the range of "localized disease"** *Leuk Res. 2006 Oct 5; [Epub ahead of print]*

Lee J, **Kim WS**, Kim K, Ahn JS, Jung CW, Lim HY, Kang WK, Park K, Ko YH, Kim YH, Park C, Yoon SH, Lee WY, Chun HK. **Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma**. *Leuk Res. 2007 Mar;31(3):359-64*

Park YH, Lee SH, **Kim WS**, Bang SM, Ryoo BY, Yang SH, Lee SS, Kim MS, Kim K, Park KW, Im do H, Kang JH, Lee J, Ko YH, Ahn YC, Lim do H, Park K. **CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation**. *Leuk Lymphoma. 2006 Jul;47(7):1253-9.*

Park YH, **Kim WS**, Bang SM, Lee SI, Uhm JE, Kang HJ, Na II, Yang SH, Lee SS,Kim K, Jung CW, Park K, Ko YH, Ryoo BY**.** **Prognostic factor analysis and proposed prognostic model for conventional treatment of high-grade primary gastric lymphoma**.
Eur J Haematol. 2006 Oct;77(4):304-8. Epub 2006 Jul 27.

Oh SY, Ryoo BY, **Kim WS**, Kim K, Lee J, Kim HJ, Kwon JM, Lee HR, Ko YH, Oh SJ, Park KW, Kim HJ, Kwon HC, Nam E, Kim JH, Park YH, Lee SS, Kim HY, Park K**.** **Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal**

zone B-cell lymphoma. *Ann Hematol. 2006 Nov;85(11):781-6. Epub 2006 Jul 18.*

Park YH, **Kim WS**, Bang SM, Lee SI, Kang HJ, Na II, Yang SH, Lee SS, Uhm JE, Kwon JM, Kim K, Jung CW, Park K, Ko YH, Ryoo BY. **Primary gastric lymphoma of T-cell origin: Clinicopathologic features and treatment outcome**. *Leuk Res. 2006 Mar 7; [Epub ahead of print]*

Park YH, **Kim WS**, Kang HJ, Na II, Ryoo BY, Yang SH, Lee SS, Uhm JE, Kim K, Jung CW, Park K, Ko YH**. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia**. *Ann Hematol. 2006 May;85(5):285-90.*

Lee SH, Ahn YC**, Kim WS**, Ko YH, Kim K, Park K, **Pre-Irradiation Dose Intense CHOP (DI-CHOP) Can't Overcome Anthracyline Resistance of Localized Nasal NK/T-cell Lymphoma** *Haematologica 2006*

Kwon JM, Park YH, Kang JH, **Kim WS**, Kim HJ, Lee HR, Kim K, Ko YH, Ryoo BY, Yang SH, Lee SS, Lee SI, Koo HH, Park K, Kang WK **The Effect of Epstein-Barr Virus Status on Clinical Outcome in Hodgkin's Lymphoma** *Ann of Hematol* 2006 Jul;85(7):463-8

Lee J , Suh C, Park YH, Ko YH , Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon H-C, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung CW, Park K , **Kim WS, Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study**. *J Clin Oncol.* 2006 Feb 1;24(4):612-8

Park BB, **Kim WS**, Lee J , Park KW, Kang JH, Lee SH, Park JO, Kim K, Jung CW, Park YS,. Im Y-H, Kang WK, Ko YH, Lee MH, Park K **IMVP-16/Pd followed by high dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell *lymphomas*** *Leukemia & Lymphoma 2005 Dec;46(12):1743-8*

Ko YH**, Kim WS**, Kim Y **Expression of CD56 antigen in Langerhans cell histiocytosis associated with T-lymphoblastic lymphoma in a same lymph node.** *Virchows Arch. 2005 Oct 14;:1-5*

Lee J, Park YH, **Kim WS**, Park SH, Park KW, Kang JH, Lee SS, Lee SI, Lee SH, Kim K, Jung CW, Ahn YC, Ko YH, Park K. **Extranodal nasal type NK/T-cell lymphoma: elucidation of clinical prognostic factors for risk based stratification of therapy** *Eur J Cancer* 2005 Jul;41(10):1402-8

Lee J, **Kim WS**, Park YH, Park SH, Park KW, Kang JH, Lee SS, Lee SI, Lee SH, Kim K, Jung CW, Ahn YC, Ko YH, Park K. **Nasal-type NK/T-Cell Lymphoma: Clinical Features and Treatment Outcome** *Br J Cancer 2005 Apr 11;92(7):1226-30*

Lee J, **Kim WS**, Kim K, Ko YH, Kim JJ, Kim YH, Chun HK, Lee WY, Park JO, Jung CW, Im Y-H, Lee MH, Kang WK, Park K. **Intestinal lymphoma: Exploration of the prognostic factors and the optimal treatment.** *Leukemia & Lymphoma 45 (2): 339-344 2004*

Song SY, **Kim WS**, Ko YH, Kim K, Lee MH, Park K **Aggressive natural killer cell leukemia: clinical features and treatment outcome**. *Haematologica. 2002 Dec;87(12):1343-5*

Kim K, **Kim WS**, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K. **Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification**. *Eur J Cancer. 2002 38(1):75-81*

Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY, Yoon SS, Lee HG, Kang WK, Lee HJ, Park CH, Park K **CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?** *Ann Oncol. 2001 12(3):349-52*

Ko YH, Ree HJ, **Kim WS**, Choi WH, Moon WS, Kim SW **Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans**. *Cancer. 2000 15;89(10):2106-16*

Lee J, Lee MH, Park KW, Kang JH, Im do H, Kim K, Lee SH, **Kim WS**, Park J, Jung CW, **Park K Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission**.
Int J Hematol. 2005 Apr;81(3):258-63.

Lee SH, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, **Kim WS**, Jung CW, Choi SJ, Lee JH, Park K **Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission**.
Biol Blood Marrow Transplant. 2005 Feb;11(2):122-8

Han SS, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Lee SH, **Kim WS**, Jung CW, Park K, Kim J, Yoon SS, Lee JH, Park S. **Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60**.
J Cell Biochem. 2005 Mar 1;94(4):695-707

Kim S, Lim do H, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, **Kim WS**, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K**. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach**. *Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1279-85*

Lee J, Im YH, Jung HH, Kim JH, Park JO, Kim K, **Kim WS**, Ahn JS, Jung CW, Park YS, Kang WK, Park K**. Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells**. *Biochem Biophys Res Commun. 2005 Aug 26;334(2):313-8*

Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, Park JO, Kim K**, Kim WS**, Jung CW, Park YS, Im YH, Park K **Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer**. *Br J Cancer. 2005 May 23;92(10):1850-4.*

Kim WS, Son HJ, Park JO, Song SY, Park C . **Promoter methylation and down-regulation of DAPK is associated with gastric atrophy**. *Int J Mol Med*. 2003;12(6):827-30

Guan Z, Wang Y, Maoleekoonpairoj S, Chen Z, **Kim WS**, Ratanatharathorn V, Reece WHH, Kim TW, Lehnert M **Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma**. *BRITISH JOURNAL OF CANCER* 89 (10): 1865-1869 17 2003

Park JO, Lee SI, Song SY, Kim K, **Kim WS**, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K. **Measuring response in solid tumors: comparison of RECIST and WHO response criteria**. *Jpn J Clin Oncol*. 2003 Oct;33(10):533-7.

Song SY, **Kim WS**, Kim K , Jung CW, Im YH, Kim HJ, Kang WK, Lee MH, Kwon OJ, Rhee CH, Park CH, Park K. **Vinorelbine, Ifosfamide, and Cisplatin Combination as Salvage Chemotherapy in Advanced Non-Small Cell Lung Cancer** *Jpn. J. Clin. Oncol. 2003 33: 509-513*

Park SH, Kim DY, Heo JS, Lim DH, Park CK, Lee KW, Choi SH, Sohn TS, Kim S, Noh JH, Kim YI, Park JO, Kim K, **Kim WS**, Jung CW, Im YH, Lee MH, Park K, Park CH, Kang WK. **Postoperative chemoradiotherapy for gastric cancer.** *Ann Oncol. 2003 Sep;14(9):1373-7*

Park WH, Jung CW, Park JO, Kim K, **Kim WS**, Im YH, Lee MH, Kang WK, Park K. **Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell cycle arrest in association with p27, or apoptosis** *Int J Oncol. 2003 22(5):1129-34*

Park WH, Jung CW, Park JO, Kim K, **Kim WS**, Im YH, Lee MH, Kang WK, Park K **Monensin inhibits the growth of renal cell carcinoma cells via cell cycle arrest or apoptosis** *Int J Oncol. 2003 22(4):855-60*

Chang HM, Jung KH, Kim TY, **Kim WS**, Yang HK, Lee KU, Choe KJ, Heo DS, Bang YJ, Kim NK. **A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer** *Ann Oncol. 2002 3(11):1779-85*

Park C, **Kim WS**, Choi Y, Kim H, Park K **Effects of transforming growth factor beta (TGF-beta) receptor on lung carcinogenesis** *Lung Cancer. 2002 Nov;38(2):143-7*

Kim K, Lee MH, Kim J, Lee KS, Kim SM, Jung MP, Han J, Sung KW, **Kim WS**, Jung CW, Yoon SS, Im YH, Kang WK, Park K, Park CH. **Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies**. *Am J Hematol. 2002 71(2):75-9*

Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E, Daglish B, Boudraa Y, **Kim WS**, Heo DS, Kim NK **Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial** *Jpn J Clin Oncol. 2002 32(7):248-54*

Kim K, Nam E, Lee NS, Lee HR, Lee JY, Lee HR, Park SH, Oh SY, Kim JH, Song SY, Park JO, **Kim WS**, Jung CW, Im YH, Lee MH, Lee WY, Chun H, Park CH, Park K, Kang WK **Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer** *Am J Clin Oncol. 2002 25(4):354-7*

Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS, Jung CW, Im YH, Yoon SS, Kang WK, Park K, Park CH, Kim SW **A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation** *Bone Marrow Transplant. 2002 29(2):137-43*

Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH, et al. **Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study** *Hum Gene Ther. 2001 12(6):671-84.*

Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH, Kang WK **Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma** *Invest New Drugs. 2001;19(1):81-3*

Woo IS, Park YS, Kwon SH, Park YL, Lee JA, Park MJ, Hyun IG, Jung KS, Bae HS, Oh DH, Kim WS, Park K, Park CH, Kim HJ, Ahn YC A phase II study of VP-16-fosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer *Jpn J Clin Oncol. 2000 30(12):542-6*

Kim WS, Park C, Hong SK, Park BK, Kim HS, Park K Microsatellite instability(MSI) in non-small cell lung cancer(NSCLC) is highly associated with transforming growth factor-beta type II receptor(TGF-beta RII) frameshift mutation *Anticancer Res. 2000 20(3A):1499-502*

Kim WS, Park C, Jung YS, Kim HS, Han J, Park CH, Kim K, Kim J, Shim YM, Park K. **Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung**. *Anticancer Res. 1999 19(1A):301-6*

Heo DS, Yoon SJ, **Kim WS**, Lee KH, Seol JG, Lee SG, Jung CW, Cho EK, Kim CW, Park MH, Sung MW, Kim KH, Bang YJ, Kim NK **Locoregional response and increased natural killer activity after intratumoral injection of HLA-B7/beta2-microglobulin gene in patients with cancer.** *Hum Gene Ther. 1998 9(14):2031-8*

Koh WS, Lee SJ, Lee H, Park C, Park MH, **Kim WS**, Yoon SS, Park K, Hong SI, Chung MH, Park CH **Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines**. *Anticancer Res. 1998 18(4A):2487-93*

Yoon SJ, Heo DS, Kang SH, Lee KH, **Kim WS**, Kim GP, Lee JA, Lee KS, Bang YJ, Kim NK. **Natural killer cell activity depression in peripheral blood and ascites from gastric cancer patients with high TGF-beta 1 expression**. *Anticancer Res. 1998 18(3A):1591-6*

Kim TY, Bang YJ, **Kim WS**, Kang SH, Lee KU, Choe KJ, Kim NK**. Mutation of ras oncogene in gastric adenocarcinoma: association with histological phenotype** *Anticancer Res. 1997 17(2B):1335-9*

Chang J, Park K, Bang YJ, **Kim WS**, Kim D, Kim **SJ Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells** *Cancer Res. 1997 15;57(14):2856-9*

Lee YY, **Kim WS**, Bang YJ, Jung CW, Park S, Yoon WJ, Cho KS, Kim IS, Jung TJ, Choi IY, et al. **Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia** *Stem Cells. 1995 13(5):556-63*

Book chapter

Extranodal lymphomas ; Patholgy and Management 1st ed. Ch 14 Nasal NK/T-cell lymphoma 2008

Cutaneous lymphoma Diagnosis and treatment Ch 11 Cutaneous extranodal natural killer/T-cell lymphoma 2012